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ABSTRACT 
Huda Al-Noumani: Health Beliefs and Antihypertensive Medication Adherence in Oman 
(Under the direction of Jia-Rong Wu) 
 Hypertension (HTN) is a serious health issue across the globe. Oman, an Arabic Muslim 
country located in the Middle East, has high prevalence of HTN and uncontrolled blood pressure 
(BP). Appropriate management of HTN and control of BP require adherence to antihypertensive 
medication to prevent HTN-related serious complications. Worldwide, proper adherence remains 
a challenge. Several factors contribute to medication adherence among patients with HTN. 
Patients’ beliefs about HTN and medication are among the significant predictors of medication 
adherence. In Oman, studies that examined patients’ health beliefs of patients with HTN as 
determinants of medication adherence are not available. Hence, this dissertation aimed to 
examine the relationship between beliefs about the necessity of and concerns about medication, 
beliefs about HTN, and self-efficacy and medication adherence among Omanis with HTN. The 
health beliefs model was used to guide this dissertation. Three manuscripts were produced to 
achieve the overall purpose of this dissertation. The first manuscript is a systematic review of 
available quantitative evidences on the relationship between patients’ different health beliefs and 
medication adherence among patients with HTN. The second and third manuscripts constituted a 
pilot study and a main study, respectively, which reported findings on the relationship between 
patients’ beliefs (HTN severity, medication necessity, medication concerns, and self-efficacy) 
and medication adherence among Omanis with HTN.  The main finding of the three manuscripts 
were that patients with stronger beliefs about the necessity of antihypertensive medications, 
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fewer concerns regarding medication (e.g., side effects), and higher self-efficacy regarding 
medication adherence significantly associated with high adherence. Findings of this dissertation 
denote that patients’ beliefs are important determinants of medication adherence and should be 
considered by clinicians and researchers to optimize adherence to antihypertensive medications. 
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CHAPTER 1: INTRODUCTION 
Though considered a developing country, Oman is a modern society in the Middle East 
that is recognized as a high-income country. The health system in Oman is well developed and 
healthcare system and resources are equally distributed with free access to all citizens. The 
Omani government primarily finances healthcare system, and, the Ministry of Health (MOH) is 
the main healthcare provider and regulator. Since its inception, the healthcare sector has aimed to 
build a healthy Omani society, through improving quality of life, health promotion, and disease 
prevention. Hence, a majority of the healthcare sector’s efforts have shifted to non-
communicable disease prevention and wellness promotion. Hypertension (HTN) is a non-
communicable disease that has been targeted by the government.  
In Oman, HTN is the second leading cause of death (14.3%) after coronary heart diseases 
(28.5%) and Oman ranks 3rd in deaths due to HTN (111 /100,000 populations) (World Health 
Rankings, 2014). Data from Oman’s Ministry of Health showed that HTN is leading cause of 
inpatient morbidity in females over 45 years of age and 2nd in males 45 - 60 years (Ministry of 
Health, 2014a). The Omani national health survey, conducted in 2008 as part of the world health 
survey by the World Health Organization and aimed to obtain baseline information about the 
health of Omani population, showed that 30% of included patients with HTN were newly 
diagnosed and 5 % have severe HTN (SBP≥180 or DBP ≥ 110 mmHg). This survey also showed 
that 75% of those who self-reported having HTN were not diagnosed at the time of the survey 
and 67% had uncontrolled BP (Al Riyami et al., 2012). In Oman, 52% of expenditures of the 
health system in Oman are due to non-communicable diseases that included cardiovascular 
  2 
diseases and HTN (Al Riyami et al., 2012). 
HTN is a major public health concern that is accountable for 45% of total mortality due 
to ischemic heart disease and 51% of total stroke deaths (World Health Organization, 2013). 
Additionally, mortality rates due to ischemic heart disease and stroke increase twofold with 20 
mmHg systolic or 10 mmHg diastolic increase in blood pressure (BP) above the optimal range 
(Chobanian et al., 2003). These complications worsen when blood pressure (BP) is not controlled 
and in the presence of other comorbidities. For instance, patients with HTN who have concurrent 
diabetes have been found to have worse BP and blood sugar control, higher medication 
utilization, and lower physical function (Al-Mandhari, Al-Zakwani, Al-Hasni, & Al-Sumri, 
2011). In the Eastern Mediterranean, the mortality rate due to HTN, cardiovascular diseases, and 
other non-communicable diseases is projected to increase by 20% between 2010 and 2020 
(World Health Organization, 2013).  
Antihypertensive medication is very important to manage HTN and control BP. High 
adherence results in better survival outcomes due to lower mortality and HTN-related 
complications than non-adherent (James et al., 2014; van Vark et al., 2012). Furthermore, 
adherence to cardiovascular medication including antihypertensive medication resulted in 10% 
reduction of the healthcare utilization and expenditure (Simon-Tuval, Triki, Chodick, & 
Greenberg, 2016).  Despite antihypertensive medication effectiveness, adherence to 
antihypertensive medication remains poor. The World health Organization reported that the 
medication adherence is only 50% in developed countries and is lower in developing countries 
(World Health Organization, 2013). In the Middle East, medication adherence is also less than 
50% (Al Qasem, Smith, & Clifford, 2011; Sulaiman, Alomar, & Strauch, 2009; World Health 
Organization, 2013).  
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Several reasons have been attributed to poor adherence with cardiovascular medications 
including antihypertensive medications, which are categorized differently. For instance these 
reasons are categorized as 1) intentional reasons (e.g., skipping medication on purpose) or 
unintentional reasons (e.g., forgetting to take medications) or as 2) predictors (e.g., age, gender, 
socioeconomic status) or barriers that are related to patients (e.g., patients’ beliefs, attitude), 
providers (e.g., patient-provider communication), health system (e.g., Access to care) (Kronish & 
Ye, 2013). Patients-related barriers to a proper medication adherence such as their beliefs have 
been identified to significantly relate to medication adherence. Various theories (e.g., the health 
beliefs model and theory of planned behavior) propose that individuals’ beliefs are strong 
predictors of their health behavior such as medication adherence (Ajzen, 1991; Rosenstock, 
Strecher, & Becker, 1988).  
Over the past decades, adherence with antihypertensive medications has been correlated 
with patients’ beliefs about HTN severity, beliefs about necessity of and concerns about 
antihypertensive medications, and self-efficacy (Bane, Hughe, & McElnay, 2006; Grégoire, 
Moisan, Guibert, Ciampi, & Milot, 2006; Horne et al., 2013; Vermeire, Hearnshaw, Van Royen, 
& Denekens, 2001). Similarly, in the Middle East, adherence to antihypertensive has been 
related to patients’ beliefs about HTN and antihypertensive medications (Al Qasem et al., 2011). 
In Oman, although many studies examined epidemiology of HTN, only one by EL-Badawy has 
examined adherence to antihypertensive medications in 2005; however, this study has not 
examined patients’ beliefs or the relationship between patients’ beliefs and medication adherence 
(El-Badawy, Al-Kharusi, & Al-Ghanemy, 2005). To date, no published study that examined the 
relationship between patient’s health beliefs and medication adherence in patients with HTN in 
Oman has been identified.  
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Purpose 
This dissertation aimed to address patients’ health beliefs and adherence to 
antihypertensive medications in Oman due to (a) the high prevalence of HTN and uncontrolled 
BP, (b) unavailability of evidence on Omani health beliefs in relation to antihypertensive 
medication adherence. The general objective of this dissertation was to examine the relationship 
between patients’ health beliefs and medication adherence among Omanis with HTN. Hence, 
specifically, the dissertation research aimed to: 
1) Describe patients’ beliefs about HTN, beliefs about antihypertensive medications’ 
necessity and concerns, and self-efficacy regarding medication adherence. 
2) Describe patients’ adherence to antihypertensive medication. 
3) Examine dependence of antihypertensive medication adherence on patients’ 
beliefs about HTN, beliefs about the necessity of and concerns related to 
antihypertensive medications, and self-efficacy. 
4) Examine dependence of BP control on antihypertensive medication adherence. 
The hypotheses were: 
(a) Patients are more likely to have high adherence if they have: 
1) Stronger beliefs that HTN is a severe disease, 2) stronger beliefs that 
antihypertensive medications are beneficial and necessary, (3) greater medication 
adherence self-efficacy, and (4) fewer concerns about antihypertensive 
medications. 
(b) Patients with high medication adherence are more likely to have their BP 
controlled. 
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Conceptual Framework 
This dissertation is based on the health belief model (HBM) (Figure 1.1). The HBM was 
developed to understand why people do not seek and engage in screening and preventive 
behavior (Becker et al., 1977; Cummings, Jette, & Rosenstock, 1987; Hochbaum, 1958). Later, 
the HBM was used to explain peoples’ responses to a disease and adherence to treatment 
regimens (Janz & Becker, 1984). The HBM consists of the following major constructs (Janz & 
Becker, 1984; Rosenstock et al., 1988):  
(a) Perceived susceptibility (beliefs of risk to contracting an illness or its 
complications). 
(b) Perceived severity (beliefs that the disease is severe and has serious 
consequences). 
(c) Perceived benefits (beliefs that taking a health behavior is beneficial to reduce 
or prevent disease threat).  
(d) Perceived barriers (beliefs that potential factors might make it difficult to 
taking the behavior). 
(e) Self-efficacy (beliefs in own ability to undertake certain behavior). 
The HBM postulates that when an individual perceives that s/he is at risk of contracting a 
serious disease (threat), s/he will initiate a certain health behavior to prevent it. However, this 
health behavior will not be adopted unless the benefits of the behavior outweigh its barriers and 
consequences. Those beliefs are potentiated by triggers (cues to action), which are internal (e.g; 
disease symptoms) or external (e.g; bodily or environmental events) (Janz & Becker, 1984; 
Rosenstock et al., 1988). Additionally, the model proposes that some variables such as 
demographics (e.g; age, gender, ethnicity, and socioeconomics) affect an individual’s beliefs; 
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thus, indirectly influence an individual’s behavior (Champion & Skinner, 2008; Janz & Becker, 
1984; Rimer & Glanz, 2005; Strecher & Rosenstock, 1997). In addition to individuals’ beliefs of 
susceptibility, severity, benefits, and barriers, self-efficacy is an important facet influencing a 
health behavior. People are more likely to take behavior if they have high self-confidence and 
believe on their ability to take that behavior (Janz & Becker, 1984; Rosenstock et al., 1988).  
Studies utilizing the HBM as a framework have demonstrated that patients’ beliefs about 
severity and susceptibility of a disease, benefits of and barriers related to medications, and self-
efficacy are related to a change in behavior such as adherence to medications (Bane et al., 2006; 
Grégoire et al., 2006; Horne, Weinman, & Hankins, 1999; Rajpura & Nayak, 2014; Vermeire et 
al., 2001). Therefore, the HBM is adopted to guide this study. Figure 1.2 displays the research 
conceptual framework that is based on HBM. Table 1.1 illustrates terms, definitions, and 
measures of the variables of the dissertation study. 
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Source: Glanz K, Rimer BK, Viswanath K, eds. 2008. Health Behavior and Health Education:  Theory, 
Research, and Practice (4th ed). San Francisco: Jossey-Bass.  
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Figure 1.1 The Health Beliefs Model 
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Table 1.1: Dissertation's Term Definitions and Measures 
Variables Definitions Measures Measures Description Psychometrics 
Beliefs about 
HTN 
 
The degree to which patients believe 
that HTN is a threatening disease. 
They include beliefs about HTN 
consequences, control, chronicity, 
concerns, and emotional impact. 
Beliefs about HTN correspond to 
beliefs about severity of and 
susceptibility to consequences of a 
disease in the HBM.   
 
Brief- Illness 
Perception 
Questionnaire (B-
IPQ)  
Nine-item scales with 8 
items use a 0 to 10-
response scale and one-
item represent subjects’ 
report of HTN causes.  
Scores range from 0-80 
A higher score reflects a 
more threatening view 
of HTN. 
 
α= 0.72. 
Test-retest 
reliability 
Concurrent, 
Predictive, 
discriminant 
validity 
 
Perceived 
necessity 
 
 
 
 
 
 
 
Perceived 
concerns 
The degree to which patients believe 
that antihypertensive medications are 
effective in controlling BP and 
reducing HTN complications. They 
correspond to beliefs about benefits in 
the HBM.    
 
 
 
The extent to which patients have 
concerns and barriers to 
antihypertensive medication intake. 
This includes concerns related to 
medications such as side effect, long-
term effects, and dependence. They 
correspond to beliefs about barriers in 
the HBM. 
 
Beliefs about 
Medication 
Questionnaire 
(BMQ)  
Five--items scale of: 
Specific-Necessity 
(BMQ-N) and six-items 
scale of Specific-
Concern (BMQ-C). 
Each has five –points 
Likert scale with (1) 
‘strongly disagree’ and 
(5) ‘strongly agree’. 
Scores of both subscales 
range from 1-5. Higher 
score indicates higher 
beliefs in concept of 
interest (Necessity or 
Concern). 
α= 0.76 each 
subscale 
Test-retest 
reliability. 
Criterion-
related and 
discriminant 
validity 
Self-Efficacy The degree to which patients believe 
that they have the confidence to take 
antihypertensive medications in 
different situations such as when they 
are busy at home, in public, travelling, 
taking more than one medications, 
Medication 
Adherence Self-
Efficacy Scale- 
Revised (MASES-
R)  
13-items scale with 4-
responses (1) not at all 
sure to (4) extremely 
sure.  Scores range from 
1-4. Higher score 
indicates higher 
α=(0.90-0.92) 
Concurrent and 
predictive 
validity
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have no symptoms and are feeling 
well, and make taking medication part 
of the life routine. This corresponds to 
self-efficacy in HBM. 
 
medication adherence 
self-efficacy 
 
Adherence to 
antihypertensive 
medication 
 
 
The extent to which patients take 
medications as prescribed.  
 
Morisky Medication 
Adherence Scale 
(MMAS-8)  
Self- report 8- items 
with seven yes/no items 
and a one item with 5-
response options. Scores 
range from 0-8. A 
higher score reflect 
higher adherence. 
 
α= 0.83. 
Concurrent and 
predictive 
validity 
BP SBP ≥ 140 mmHg and/or DBP ≥ 90 
mmHg is considered as uncontrolled  
Electronic medical 
records 
SBP < 140 and/or DBP 
< 90 will be considered 
as controlled. 
Not Applicable 
  Age, gender, marital status, Governorate, city, education, monthly 
income, number of antihypertensive medications, length being on 
medication, dose frequency per day, number of months/years with 
HTN, systolic BP (SBP), diastolic BP (DBP), and CCI. 
 
Note: α= Cronbach’s alpha (Internal consistency) 
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Study Setting Overview 
In Oman, the healthcare system is designed to provide primary-level healthcare through 
its primary health centers and polyclinics. These primary healthcare settings are spread all over 
the 11 governorates of Oman and only provide outpatient care. Moreover, each Governorate has 
one or more of the state reference hospitals that provide secondary–level curative and preventive 
healthcare services. These hospitals refer the complicated pathological cases to tertiary–level 
healthcare hospitals, which are situated in Muscat Governorate. Tertiary–level hospitals provide 
advanced specialties and sub–specialties services. In this research, subjects with HTN were 
recruited from multiple primary healthcare settings (e.g. health centers) around the country in 
order to obtain a heterogeneous sample. Those primary healthcare settings have on-site HTN 
clinics, which provide the researcher with the potential subjects. Those clinics are operated once 
or more a week. Each clinic sees a minimum of 5 patients with HTN per day. In this study, 
clinics from different Governorates of Ad Dhakhliyah, North Ash Sharqiyah, Muscat, Ad 
Dhahirah, North and South Al Batinah are utilized to recruit subjects.  
Significance of the Study to Oman 
This dissertation is in alignment with the research priorities of the Ministry of Health 
(MOH) in Oman, which focuses on reducing HTN prevalence, risk factors, and complications as 
well as improving screening, control, and treatment adherence. Additionally, it is in alignment 
with the MOH’s Health Vision 2050 that emphasizes on patient-centered care to improve 
patients’ involvement in their care and enhance treatment adherence and accordingly, making 
positive behavioral changes (Ministry of Health, 2014b). The results of this study will provide 
the foundation to examine beliefs in relation to antihypertensive medication adherence. 
Therefore, the results can (a) positively impact researchers and clinicians to develop effective 
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and culturally appropriate interventions that take patients’ health beliefs into consideration to 
improve medication adherence among Omanis with HTN; (b) be the precursor for improving 
adherence to pharmacological and non-pharmacological management of HTN, and more 
significantly, (c) help in reducing the economic burden by preventing uncontrolled BP 
complications.  
Dissertation Plan 
Chapter 1 is the problem statement, conceptual framework, and significance of the study 
to Oman.  Chapter 2, 3, and 4 of the dissertation are structured in three publishable manuscripts. 
Chapter 2 (Manuscript 1), titled “Beliefs and Medication Adherence in Patients with Hypertension: A systematic	Review”,	presents a systematic review that identifies and compiles 
the current literature on HTN, beliefs, and medication adherence. The aim of this review is to 
examine the relationship between patients’ health beliefs and antihypertensive medication 
adherence. Chapter 3 (Manuscript 2), titled “Relationship between Medication Adherence and 
Beliefs among Patients with Hypertension in Oman”, presents results from the pilot study that 
was conducted in Oman to examine feasibility of the study, to test the study Arabic measures in 
Omani populations, and to obtain a preliminary data on the relationship between patients’ health 
beliefs and medication adherence. Chapter 4 (Manuscript 3), titled “Medication Adherence and 
Health Beliefs among Omanis with Hypertension”, presents findings from the proposed study 
that describes patients’ beliefs about HTN, beliefs about medications, self-efficacy, and 
medication adherence among Omanis with HTN. Also, it presents findings on the relationship 
between beliefs and medication adherence, and the relationship between medication adherence 
and BP control. Chapter 5 is an overall synthesis and discussion of the three manuscripts 
findings. This chapter provides implications for practice, future research, and policy.  
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CHAPTER 2: BELIEFS AND MEDICATION ADHERENCE IN PATIENTS WITH 
HYPERTENSION: A SYSTEMATIC REVIEW  
Introduction 
Hypertension (HTN) is a prevalent health concern around the globe that affects about 
40% of the world’s population aged 25 years and older (Alwan, 2011). Effective HTN 
management, using antihypertensive medications, is vital and leads to substantial improvements 
in patients’ health outcomes (e.g., blood pressure (BP) control, complications risk reduction) and 
in overall healthcare (e.g., cost reduction) (Blood Pressure Lowering Treatment Trialists' 
Collaboration et al., 2013; Matsumura et al., 2012; Simon-Tuval, Triki, Chodick, & Greenberg, 
2016). Despite the guidelines regulating HTN management, control of BP remains a challenge 
for many patients with HTN. Proper adherence to antihypertensive medications is only 50% or 
less, which contributes to poor control of BP (World Health Organization, 2013). 
Medication adherence is linked to several factors (Gellad, Grenard, & Marcum, 2011; 
Jackson, Clatworthy, Robinson, & Horne, 2010) that require understanding before 
implementation of strategies to improve adherence to antihypertensive medications (McDonald, 
Garg, & Haynes, 2002; Morrison, Wertheimer, & Berger, 2000; Schroeder, Fahey, & Ebrahim, 
2004). Patients’ beliefs about health, illness, and treatment are significant predictors of 
medication adherence in patients with various chronic illnesses including HTN  (Broadbent, 
Donkin, & Stroh, 2011; Brown & Bussell, 2011; Gadkari & McHorney, 2012; Horne et al., 
2013; Schüz et al., 2011; Van Den Bemt, Zwikker, & Van Den Ende, 2014). In treating HTN, 
understanding patient’s beliefs in relation to medication adherence is fundamental because HTN 
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is silent and asymptomatic in nature. Thus, patients might have misperceptions about HTN, its 
severity, and the significance of its management (Center for Health Protection, 2016; Marshall, 
Wolfe, & McKevitt, 2012; World Health Organization, 2013), which could influence their 
adherence to antihypertensive medication. 
After a thorough search of related literature, we found two reviews focused on barriers to 
antihypertensive medication adherence, but they included very limited studies concerning beliefs 
as possible barriers (AlGhurair, Hughes, Simpson, & Guirguis, 2012; Khatib et al., 2014). 
Another review focused on examining patients’ beliefs on HTN and medication adherence 
(Marshall et al., 2012); however, this was a review of qualitative studies and excluded findings 
from quantitative studies. Over the past decades, several quantitative studies have found that 
various beliefs held by patients influence medication adherence (Ambaw, Alemie, Yohannes, & 
Mengesha, 2012; Bhandari, Sarma, & Thankappan KR, 2011; Cummings, Kirscht, Binder, & 
Godley, 1982; Forsyth, Schoenthaler, Chaplin, Ogedegbe, & Ravenell, 2014; Hashmi et al., 
2007; Morrell, Park, Kidder, & Martin, 1997); nevertheless, we identified no reviews 
summarizing and synthesizing these studies’ findings. Hence, this systematic review of 
quantitative studies was conducted to explicitly identify different HTN-related health beliefs and 
to examine the relationship between these beliefs and medication adherence. The examination of 
the relationship between different patients’ beliefs and adherence to antihypertensive 
medications among patients with HTN will guide the development of effective strategies to 
enhance medication adherence by incorporating patients’ specific beliefs and perspectives into 
patient-centered treatment plans. 
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Method 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines was used to guide the review (Moher, Liberati, Tetzlaff, & Altman, 2009). The search 
was done in collaboration with a librarian and included the following electronic databases: 
PubMed, CINHAL, EMBASE, and PsychInfo. To retrieve appropriate articles, the following 
Medical Subject Headings (Mesh) and text-words were used in PubMed: adherence [tw] OR 
compliance [tw]) AND (attitude*[tw] OR belief*[tw] OR perception*[tw] OR perceiv*[tw] OR 
psychosocial [tw]) AND ("Antihypertensive Agents"[Mesh] OR "Antihypertensive Agents" 
[Pharmacological Action] OR antihypertensive agent*[tw] OR medication*[tw]) AND 
(hypertension [tw] OR hypertensive [tw]. The same search strategy was used with other 
databases as well, with Mesh and text-words appropriately modified to fit each database. The 
search was restricted to English, peer-reviewed, and full text research articles. There were no 
limitations on geographical location, year of publication, or type of patients’ beliefs because this 
review aimed to identify all possible beliefs and to include all possible studies matching the 
purpose of this review.  
Eligibility Criteria 
Studies were included in the review if they (a) were quantitative; (b) included participants 
with HTN taking at least one antihypertensive medication who were ≥18 years (because a 
majority of literature on HTN and medication adherence included participants with a minimum 
age of 18 years); (c) addressed patients’ beliefs; and (d) measured medication adherence as an 
outcome variable. Studies were excluded if they (a) were qualitative, as a review of qualitative 
studies was already conducted (Marshall et al., 2012); (b) focused only on providers’ beliefs; or 
(c) included subjects with concomitant morbidities in addition to HTN or had medications other 
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than antihypertensive medications because having concomitant morbidities will influence 
patients’ perceived burdens and the severity of a disease and its management (Amr, El-Mogy, & 
El-Masry, 2013).  
Review Process 
All retrieved articles were organized and screened using a Microsoft Excel spread sheet and 
Refworks reference management software. After removing duplicates, articles’ titles and 
abstracts were assessed for eligibility. Then, the full-text articles were screened and data of the 
eligible articles were extracted into a table. Extraction of the data was based on the following 
categories: authors, publication year, theory, sample size and population, mean age and gender, 
types of beliefs, adherence measure, and findings. Quality of the studies was evaluated using the 
Quality Assessment Tool for Systematic Review of Observational Studies (QATSO) checklist 
(Wong, Cheung, & Hart, 2008) , which was slightly modified to fit the review (See Appendix 
2.1). The QATSO consists of items to assess external validity, bias and confounding, and 
measures’ validity/reliability. Relevant articles were not excluded based on quality evaluation 
because the purpose of the review was to identify as many beliefs as possible.  
Results 
Selection of the Studies 
The electronic search yielded 1,388 articles (Figure 2.1). After removing duplicates (n= 
346), 1,042 articles remained. Of these, 809 articles were excluded after title and abstract 
screened applying inclusion and exclusion criteria. The remaining 233 full text articles were 
further screened for eligibility. Of these, 208 articles were excluded because these articles: (a) 
included subjects who had other comorbidities in addition to HTN (n=79); (b) did not address 
patients’ beliefs (n=27); (c) did not measure medication adherence or measured adherence to 
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other therapeutic behaviors (e.g., diet and exercises) (n=53); (d) measured adherence of 
medications other than antihypertensive (n=8); (e) did not measure adherence as an outcome 
variable (n=8); or (f) were qualitative studies (n=7). The remaining 25 studies were included in 
the systematic review.  
Methodological quality evaluation of the studies revealed that 80% (n=20) of the 
reviewed studies scored from satisfactory to good (Table 2.1). Although 84% (n=21) of the 
studies reported validity and reliability of the adherence measures, a majority of them used only 
self-reporting measures (n=19), and the remaining used either objective measure only, or both. 
However, self-report measures, such as Morisky Medication Adherence Scale (MMAS), have 
been correlated with other objective measures such as pharmacy refills and the Medical Events 
Monitoring System (MEMS) (Hamilton, 2003; Morisky, Ang, Krousel-Wood, & Ward, 2008). 
Moreover, a majority of studies used non-probability sampling (n=16), which could limit the 
studies’ external validity.
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PubMed (n= 550) 
Embase (n= 722) 
CINAHL (n= 84) 
PsycInfo (n= 32)  
1,388 articles identified 
through database searching  
 
346 duplicate 
1,042 articles titles and abstracts 
screened  
 
809 articles excluded  
208 full text articles excluded:  
 
x 6 were books, not research articles, 
dissertation. 
x 8 were not in English. 
x 79 addressed other comorbidities 
x 53 did not measure medication 
adherence, but measure adherence to 
other therapeutic behaviors.. 
x 27 did not address patients’ beliefs or 
perception 
x 8 measures adherence of other 
medications with antihypertensive 
medications. 
x 4 not full text-articles 
x 8 instrument development 
x 8 did not measure adherence as an 
outcome variable. 
x 7 qualitative study 
 
 
233 full text articles assessed 
for eligibility 
 
25 studies included in the 
final analysis  
Figure 2.1 Flow Diagram of the Selection Process of the Studies 
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Characteristics of the Studies 
The 25 studies reviewed appeared from 1980−2016 (Table 2.2). The studies’ sample sizes 
ranged from 45 to 1,367 participants with a total of 6,696 participants. The samples represented 
people from the following countries: Canada (n=1), Brazil (n=2), South Africa (n=1), Northern 
Ireland (n=1), Malaysia (n=1), the Netherlands (n=1), Taiwan (n=1), India (n=1), Peru (n=1), 
Iran (n=1), the United Kingdom (n=1), Australia (n=1), Nigeria (n=1), and the United States 
(n=11). Studies from the United States included the following ethnicities: White American, 
African American, Native American, Hispanic, Chinese American, and Caucasian. The mean age 
of participants included in the studies ranged from 42−75 years old. Both males and females 
were included in the studies, with the percentage of females ranging from 2−84%, except in the 
case of Haynes (1980) who included 100% no females.  
Twenty-four studies, (96%), had cross-sectional designs, and only one study had a 
longitudinal design (Haynes et al., 1980). Of the 25 included studies, nine included a randomized 
sample (Brown & Segal, 1996; Dennis et al., 2011; Haynes et al., 1980; Hershey, Morton, Davis, 
& Reichgott, 1980; Hong, Oddone, Dudley, & Bosworth, 2006; Kamran, Ahari, Biria, Malepour, 
& Heydari, 2014; Morisky et al., 2008; Olowookere et al., 2015; Ungari & Fabbro, 2010). The 
majority of the studies used one measure to assess medication adherence, one study used three 
measures (i.e., medication event monitoring system, Morisky medication adherence scale, and 
the medication adherence report scale) (Alison Phillips, Leventhal, & Leventhal, 2013), and 
another study used four measures of medications adherence (i.e., pill counts, serum uric acid, 
urinary chlorthalidone, and self-reports) (Haynes et al., 1980). Self-report measures were used by 
92% of studies (n= 23); of these, the Morisky Medication Adherence Scale was used in nine 
studies (36%). Thirty-six percent of studies (n= 9) used a theoretical model: the health beliefs 
  23 
model (Brown & Segal, 1996; Hassan et al., 2006; Kamran et al., 2014; Peltzer, 2004), self-
efficacy and the theory of planned behavior (Bane, Hughe, & McElnay, 2006), self-regulation 
model (Chen, Tsai, & Lee, 2009), medication adherence model (Hsu, Mao, & Wey, 2010), 
commonsense self-regulation model (Alison Phillips et al., 2013), and ecological system theory 
(Hall, Lee, Clark, & Perilla, 2014).  
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Table 2.1. Quality Assessment of the Studies Included in the Review 
 
Authors / Pub 
Year  
 
 
Sampling 
Method 
 
 
Response 
Rate 
mentioned  
 
 
Adherence 
Measure 
validity and 
Reliability 
 
Adherence 
Measure 
(Objective, 
self-report,)  
 
 
Control of 
Confounding 
factors  
 
Total 
Percentage* 
 
 
Quality Score** 
Alison,et al.  
(2013) 
Non-probability No Yes Objective Yes 60 % Satisfactory 
Bane et al.,  
(2006) 
Non-probability No Yes Objective Yes 60 % Satisfactory 
Brown & Segal 
(1996) 
Probability Yes Yes self-report Yes 80 % Good 
Chen et al  
(2009) 
Non-probability No Yes Objective Yes 60 % Satisfactory 
Daniel & Veiga 
(2013) 
Non-probability No No self-report NA 0 % Bad 
Dennis et al 
 (2011) 
 
Probability No Yes self-report Yes 60 % Satisfactory 
Dijkstra et al 
 (2008) 
Non-probability No No self-report Yes 20 % Bad 
Fernandez-Arias 
et al  (2014) 
Non-probability No Yes self-report Yes 40 % Satisfactory 
Gilbert et al  
(1990) 
Non-probability Yes Yes Objective NA 75 % Good 
Hall et al 
(2014) 
 
Non-probability No Yes self-report Yes 40 % Satisfactory 
Hassan et al, 
 (2006) 
Non-probability Yes Yes self-report Yes 60 % Satisfactory 
Haynes et al,  
(1980) 
Probability Yes Yes Objective No 80 % Good 
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Hershey et al, 
(1980) 
Probability Yes No self-report Yes 60 % Satisfactory 
Hong et al 
(2006) 
Probability No Yes self-report Yes 60 % Satisfactory 
Hsu et at 
 (2010) 
Non-probability No Yes self-report NA 25 % Bad 
Kamran et al, 
(2014) 
Probability No Yes self-report Yes 60 % Satisfactory 
Khan et al., 
(2014) 
Non-probability No Yes self-report NA 25 % Bad 
Morisky et al, 
(2008) 
Probability Yes Yes self-report Yes 80 % Good 
Okowookere et 
al, (2015) 
Probability No Yes Objective NA 75 % Good 
Patel & Taylor 
(2002) 
Non-probability Yes Yes self-report No 40 % Satisfactory 
Peltzer (2004) Non-probability No Yes self-report No 20 % Bad 
Richardson et al, 
(1993) 
Non-probability No Yes self-report Yes 40 % Satisfactory 
Trevino et al, 
(1990) 
Non-probability No Yes self-report Yes 40 % Satisfactory 
Ungari & Fabbro 
(2010) 
Probability No Yes self-report No 40 % Satisfactory 
Wong et al, 
(2005) 
Non-probability Yes No self-report Yes 40 % Satisfactory 
Note: NA = Not Applicable. 
*Scoring: Total score (0/1) divided by total number of items multiplied by 100 
**Bad = 0 - 33%; Satisfactory = 34 - 66%; Good = 67 – 100% 
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Table 2.1. Characteristics of the Studies 
 
Authors/Year  
 
 
Theory 
Used 
 
Design 
 
Sample size (n) 
Population 
 
 
Mean Age 
Gender  
 
         Beliefs Type 
 
Medication Adherence 
Measure 
 
Alison 
Phillips, et al.  
(2013) 
Commonsense 
self-regulation 
model 
 
Cross-
sectional 
n = 71 
White, Africa-
American, 
Asian, Native 
American, 
Hispanic 
M=68 
63% (F) 
 
1. Necessity of 
medications 
 
1. Medication Event 
Monitoring System*  
2. Morisky Medication 
Adherence Scale * 
3. Medication 
Adherence Report 
Scale * 
Bane et al,  
(2006) 
Self-efficacy 
Theory of 
planned 
behavior 
Cross-
sectional 
 
n = 139 
Northern Ireland 
M= 52 
50% (F), 
 
1. Perception of self-
efficacy 
2. Perception of subjective 
norms 
 
 
1. 1. Self-report 
2. 2. Patient medication 
report* 
Brown & 
Segal 
 
(1996) 
HBM Cross- 
sectional 
n = 300 
African-
American/White 
Americans 
M= 60 
56% (F) 
1. Perception of 
susceptibility 
2. Perception of severity 
3. Benefits of medication 
4. Cost of medication 
5. Side effects of 
medication 
  1. Self-report* 
Chen et al, 
(2009) 
Self-
Regulation 
model 
Cross- 
sectional 
n = 277 
Taiwanese 
 
M=66 
40% (F) 
1. Illness perception 
2. Self-efficacy 
(Treatment and 
personal control) 
1. The Medication 
Adherence 
Inventory*  
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Daniel & 
Veiga (2013) 
None Cross-
sectional 
n = 69 
Brazilian 
M=64 
67% (F) 
1. Side effects of 
medication 
2. Cost of medication 
3. Doctor-patient 
communication 
1. Self-report 
 
Dennis et al 
(2011) 
 
None 
 
 
Cross 
sectional 
n = 608 
Urban Indian 
 
M=58 
49% (F) 
1. Medication barriers 
- Cost 
1. Brief Medication 
Questionnaire * 
Dijkstra et al 
(2008) 
None Cross-
sectional 
n = 176 
Netherlands 
M= 62 
52% (F) 
1. HTN severity 
 
1. Self-report (1-item)  
Fernandez-
Arias et al 
(2014)   
 
None 
 
 
Cross-
sectional 
 
 
n = 115 
Peru 
 
M=62 
67% (F) 
1. Medication harm 
2. Medication Concern 
3. Medication Necessity 
1. Morisky Medication 
Adherence Scale (8-
items)* 
 
 
Gilbert et al 
(1990) 
None Cross-
sectional 
n = 110 
Australian 
M= 59 
55% (F) 
1. Self-efficacy 1. Prescription re-fill* 
2. Self-report of 
consumption 
 
Hall et al  
(2014) 
 
Ecological 
System Theory 
 
Cross-
sectional 
 
 
n = 45 
Hispanic 
 
28-60 
56% (F) 
 
1. Perceived stress 
 
 
1. Morisky Medication 
Adherence Scale (8-
items)* 
 
Hassan et al 
(2006) 
HBM Cross-
sectional 
 
n = 240 
Malaysian 
M= 55 
50% (F) 
1. Severity of HTN 
2. Susceptibility to HTN 
consequences 
3. Barriers (complex 
regimen, cost) 
1. Self-report* 
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Haynes et al 
(1980) 
None Longitudinal
/ 6 months 
follow-up 
n = 134 
Canadian 
M= 42 
100% (M) 
1. Medication safety 
2. Medication benefits 
3. HTN seriousness 
 
1. Pill count* 
2. Serum Uric acid and 
potassium 
determination* 
3. Urinary 
chlorthalidone and 
hydrochlorothiazide
* 
4. Self-report 
Hershey et al 
(1980) 
None Cross-
sectional 
n = 132 
92% Black and 
white Americans 
M= 52 
61% (F) 
1. Susceptibility  
2. Severity of HTN 
3. Benefits of medications 
4. Concerns about health 
5. Control over HTN 
6. Dependence on the 
provider 
7. Barriers 
1. Self-report 
Hong et al 
(2006) 
None Cross-
sectional 
n = 588 
White/African 
American 
M= 63 
2% (F) 
1. Barriers (side-effects, 
complex regimen, 
forgetting) 
2. Internal locus of control 
1. Self-report (Morisky 
4-items)* 
 
Hsu et al. 
(2010) 
Medication 
Adherence 
Model 
 
Cross-
sectional 
 
n = 94 
Chinese 
American 
M= 75 
63% (F) 
1. Necessity and 
effectiveness of 
medication 
2. Side-effects 
medication 
3. Safety 
1. Hill-Bone 
Compliance*  
2. The Adherence 
Factor 
Questionnaire*  
Kamran et al., 
(2014) 
 
HBM 
 
 
Cross-
sectional 
 
n = 671 
Iran 
>30 
75% (F) 
 
1. Severity of HTN 
2. Susceptibility to HTN 
consequences 
3. Benefits of 
medications 
4. Barriers 
5. Self-efficacy 
1. Morisky Medication 
Adherence Scale (4-
items)* 
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Khan et al., 
(2014) 
None Cross-
sectional 
 
n = 200 
UK 
>18 
62% (F) 
1. Side-effects 
 
1. Morisky Medication 
Adherence Scale (4-
items)* 
Morisky et 
al., (2008) 
None Cross-
sectional 
n = 1367 
American 
M= 62 
59% (F) 
1. Health status 
2. Social support 
3. Stress 
1. Self-report (Morisky 
4-items, & 8- 
items)* 
2. Blood pressure 
Okowookere 
et al, 
(2015) 
None Cross-
sectional 
n = 420 
Nigerian 
M= 61 
51% (F) 
1. Family Support 1. Bill count* 
       
Patel & 
Taylor 
(2002) 
None Cross-
sectional 
n = 102 
80% white 
M=59  
60% (F) 
1. Control over HTN 1.  Self-report (Morisky 
4-items)* 
Peltzer, 
(2004) 
HBM Cross-
sectional 
n = 100 
South African 
M=61 
67% (F) 
1. Benefits of medication 
2. Side effects & cost of 
medication 
3. Severity of HTN 
4. Susceptibility to HTN 
consequences 
1. Self-report on 
adherence* 
Richardson et 
al  
(1993) 
None Cross-
sectional 
 
n = 197 
American 
M= 54 
 
68% (F) 
1. Barriers  1. Self-report* 
2. Provider interview 
Trevino et al.,  
(1990) 
None 
 
Cross-
sectional 
 
n = 109 
American 
M= 50 
 
58% (F) 
1. Marital adjustment 
and function 
 
 
1. Self- report 
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Ungari & 
Fabbro, 
(2010) 
None Cross-
sectional 
 
n = 109 
Brazilian 
> 20 yrs 
84% (F) 
1. Trust in doctors 1. Morisky 
Medication 
Adherence Scale (4-
items)* 
 
 
Wong et al., 
(2005) 
None Cross-
sectional 
n = 323 
Hmong 
American 
M=58. 
60% (F) 
1. HTN preventable 
2. Side-effects 
1. self-report 
Note: HBM = Health Belief Model; M = Mean age; F = Female 
* Reliability and validity reported 
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Relationship Between Beliefs and Medication Adherence 
  The systematic review revealed that some patients’ beliefs were negatively related (e.g., 
medication concerns), some were positively related (e.g., severity of HTN), and other beliefs had no 
significant relationship with to antihypertensive medication adherence (Table 2.3). Findings of this 
review were categorized based on belief types: (a) beliefs about hypertension (e.g., severity of 
HTN); (b) beliefs about antihypertensive medications (e.g., barriers, effectiveness); and (c) other 
patient-related beliefs (e.g., self-efficacy, perceived patient-provider relationship, and perceived 
stress.  
Beliefs About Hypertension. Nine studies (36%) examined beliefs about the severity of 
HTN and susceptibility to its complications in relation to antihypertensive medication adherence. 
Beliefs about severity of HTN, this is patients’ perceptions about the seriousness of HTN, were 
reported in seven studies; three studies found that higher perception of HTN severity was 
significantly related to higher medication adherence (Haynes et al., 1980; Kamran et al., 2014; 
Wong, Mouanoutoua, Chen, Gray, & Tseng, 2005) whereas four studies reported no relationship 
(Brown & Segal, 1996; Hassan et al., 2006; Hershey et al., 1980; Peltzer, 2004).  
Patients’ beliefs regarding their susceptibility to HTN−related complications were 
reported in seven studies and revealed mixed results. Two studies reported that as beliefs about 
susceptibility to complications increased, the medication adherence increased significantly 
(Dijkstra, Okken, Niemeijer, & Cleophas, 2008; Kamran et al., 2014). One study found that as 
beliefs about susceptibility to complications increased, medication adherence decreased (Chen et 
al., 2009), and four studies reported no relationship (Brown & Segal, 1996; Hassan et al., 2006; 
Hershey et al., 1980; Peltzer, 2004).  
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Beliefs About Antihypertensive Medications. Sixteen studies (64%) reported beliefs 
about barriers to taking antihypertensive medications and beliefs about medications 
effectiveness/benefits, safety, and necessity. Perceived barriers to taking medications were 
reported by 13 studies; of these, 11 studies found that stronger beliefs in barriers to taking 
medications such as medications’ side effects, high cost, bad taste, and harmful effects, were 
significantly associated with lower medication adherence (Brown & Segal, 1996; Daniel & 
Veiga, 2013; Fernandez-Arias, Acuna-Villaorduna, Miranda, Diez-Canseco, & Malaga, 2014; 
Hassan et al., 2006; Hershey et al., 1980; Hong et al., 2006; Kamran et al., 2014; Khan, Shah, & 
Hameed, 2014; Peltzer, 2004; Richardson, Simons-Morton, & Annegers, 1993; Wong et al., 
2005). However, two studies reported no relationship between beliefs concerning side effects of 
medication and medication adherence (Hsu et al., 2010) or between medication cost and 
medication adherence (Dennis et al., 2011).  
Additionally, of eight studies examining beliefs about effectiveness, necessity, and safety 
of medications, five examined the relationship between medications’ effectiveness/benefits and 
medication adherence; of these, two studies reported that stronger beliefs about the effectiveness 
of antihypertensive medications were associated with higher medication adherence (Kamran et 
al., 2014; Peltzer, 2004) and three studies found no relationship (Brown & Segal, 1996; Haynes 
et al., 1980; Hershey et al., 1980). Three studies examining beliefs about medications’ necessity 
and safety did not find a relationship between perceived medications’ necessity and adherence 
(Alison Phillips et al., 2013; Fernandez-Arias et al., 2014; Hsu et al., 2010) or between 
medication safety and adherence (Hsu et al., 2010). Only one study found that stronger beliefs of 
medication safety were related to higher medication adherence (Haynes et al., 1980).  
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Other Patient-Related Beliefs. Eleven studies examined other beliefs in relation to 
antihypertensive medication adherence. These studies reported that higher adherence was related 
to (a) higher self-efficacy, patients’ beliefs about their own capabilities to perform a certain 
behavior (Bane et al., 2006; Chen et al., 2009; Gilbert, Owen, Sansom, & Innes, 1990; Kamran et 
al., 2014); (b) higher internal locus of control (i.e., the degree to which people believe that their 
health status is influenced by their own behavior (Hong et al., 2006); (c) higher subjective norms 
(i.e., beliefs that taking medications is important because significant others believe it is important 
(Bane et al., 2006) ; (d) perceived good general health (Morisky et al., 2008); (e) perceived good 
relationship with healthcare providers (Hershey et al., 1980; Ungari & Fabbro, 2010) ; (f) 
perceived good relationship with spouses (i.e., marital function;  (Trevino, Young, Groff, & 
Jono, 1990) ; (g) perceived good control over HTN (Hershey et al., 1980); and (h) perceived 
strong family support (Olowookere et al., 2015). However, medication adherence was lower with 
more perceived stress (Morisky et al., 2008) and control over HTN (Patel & Taylor, 2002). Other 
studies reported no relationship between perceived stress and adherence (Hall et al., 2014) or 
between general concerns about health and adherence (Hershey et al., 1980). 
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Table 2.2. Findings of the Studies 
 
1. Beliefs about hypertension 
 
 
 
Severity 
Haynes (1980) *  
Kamran (2014) ***  
Wong (2005) ***  
 
Positive association  
Higher perceived seriousness of HTN is related to higher 
medication adherence. 
Brown (1996)   
Hassan (2006) 
Hershey (1980)   
Peltzer (2004)  
 
 
No association 
 
Perceived seriousness of HTN is not related to medication 
adherence. 
 
 
 
 
 
Susceptibility  
Dijkstra (2008)  *  
Kamran (2014) **  
 
Positive association  
Higher perceived susceptibility to HTN/ complications is 
related to higher medication adherence. 
 
Brown (1996)   
Hassan (2006)  
Hershey (1980)     
Peltzer (2004)  
 
 
No association 
 
Perceived susceptibility to HTN/ complications is not related 
to medication adherence. 
 
 
Chen (2009) * Negative association  Higher perceived susceptibility to HTN/ complications is 
related to lower medication adherence. 
 
 
2. Beliefs about Antihypertensive Medications 
 
 
 
 
 
Barriers: 
Side-effects 
Taste 
Cost 
Harm 
 
Brown (1996) *  
Daniel (2013)#  
Fernandez-Arias (2014) ** 
Hassan (2006) ** 
Hershey (1980) *  
Hong (2006) *** 
Kamran (2014) ***  
Khan (2014)#  
Richardson (1993) *  
Peltzer (2004)  *** 
Wong (2005) * 
 
 
 
 
 
 
Negative association 
 
 
 
 
More perceived barriers to taking medications are related to 
lower medication adherence. 
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Dennis (2011) 
Hsu (2010)  
 
No association 
 
Perceived barriers to taking medications are not related to 
medication adherence. 
 
 
Benefits/Effectiveness 
 
Kamran (2014) ** 
Peltzer (2004)  ** 
 
Positive association 
Higher perceived effectiveness of antihypertensive 
medications is related to higher medication adherence. 
 
Brown (1996)   
Haynes (1980)      
Hershey (1980)     
 
 
No association 
 
Perceived medication effectiveness is not related to 
medication adherence. 
 
 
 
Necessity 
Alison (2013)  
Fernandez-Arias (2014) 
Hsu (2010)  
 
No association 
Perceived medication Necessity is not related to medication 
adherence. 
 
Safety 
Haynes (1980) *  Positive association Higher perceived safety of medication is related to higher 
medication adherence. 
 
Hsu (2010)  No association Perceived medication safety is not related to medication 
adherence. 
 
3. Other Beliefs 
 
Self-efficacy 
 
Bane (2006)  *** 
Chen (2009) ** 
Gilbert (1990)# 
Kamran (2014) ***  
Positive association 
 
 
Higher self-efficacy is related to higher medication 
adherence. 
 
Internal locus of control Hong (2006) * Positive association 
 
Higher Internal locus of control is related to higher 
medication adherence. 
 
Patient- provider 
communication 
Hershey (1980) *  
Ungari (2010) * 
Positive association 
 
Higher self-efficacy is related to higher medication 
adherence. 
 
Control over HTN Hershey (1980) *  Positive association Higher perceived control over HTN is related to higher 
medication adherence. 
 
Patel (2002) **  Negative association Higher perceived control over HTN is related to Lower 
medication adherence. 
 
 Morisky (2008) *  Negative association Higher perceived stress is related to lower medication 
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Stress adherence. 
 
Hall (2014)  No association Perceived stress is not related to medication adherence. 
 
Marital Adjustment Trevino (1990) **  Positive association Perception of good marital relationship is related to higher 
medication adherence. 
 
Family support Olowookere (2015)*** Positive Association Stronger perception of family support is related to higher 
medication adherence 
Subjective Norms Bane (2006)  ** Positive association Subjective norms are related to higher medication adherence. 
 
General health status Morisky (2008) *  Positive association Perception of good general health status is related to higher 
medication adherence. 
 
Concern about health Hershey (1980) No association Perceived concern about health is not related to medication 
adherence. 
 
Note: * p-value ≤ .05         ** p-value ≤ .01       *** p-value ≤  .001       # used only descriptive statistics 
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Discussion 
This systematic review identified 25 quantitative studies examining the relationships 
between different patients’ beliefs and medication adherence among patients with HTN. The 
review identified these common beliefs related to antihypertensive medication adherence: beliefs 
about medications (e.g., effectiveness and necessity and barriers), beliefs about HTN (e.g., 
severity and susceptibility to consequences), and self-efficacy. 
A majority of the studies examining beliefs about medications (11 out of 13) found a 
negative association between barriers to taking medications and medication adherence; these 
findings are similar to those of other reviews conducted among patients with HTN and other 
chronic diseases (AlGhurair et al., 2012; Marshall et al., 2012; Van Den Bemt et al., 2014; 
Verbrugghe, Verhaeghe, Lauwaert, Beeckman, & Van Hecke, 2013). Additionally, our findings 
are consistent with those of studies included in the meta-analysis by Horne and colleagues 
(2013), who found that medication adherence was significantly higher in patients with fewer 
concerns regarding medications’ side effects and safety. Findings from this review and others 
underline the importance of ssessing patients’ perceived barriers to medication adherence (e.g., 
side effects) to identify the best strategies for enhancing medication adherence.  
Four studies in this review reported a positive relationship between beliefs about severity 
of HTN and their susceptibility to its complications and medication adherence, which is 
consistent with the findings of other reviews examining barriers to medication adherence among 
patients with HTN (AlGhurair et al., 2012), patients with chronic conditions (Van Den Bemt et 
al., 2014), and elderly patients (Gellad et al., 2011), which found that medication adherence was 
less likely among patients who believed that HTN is not severe and that they were at low risk of 
developing HTN complications. Four other studies of our review reported no association and one 
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found a negative relationship. These mixed findings could be related to the influence of culture 
on how people view illness causality, severity, and susceptibility to complications, especially 
because HTN is silent in nature. In our review, studies that examined these beliefs represented 
people from different cultural backgrounds (e.g., Canada, Brazil, South Africa, Northern Ireland, 
Malaysia, the Netherlands, Taiwan, India, Peru, Iran, the United Kingdom, Australia, Nigeria, 
and the United States) that might perceive HTN differently. For instance, adherence to 
antihypertensive medications was lower among Americans who attributed HTN to bad deeds 
(Wong et al., 2005) and Chinese who attributed HTN to cultural causality (e.g., imbalance 
between internal and external environment (Chen et al., 2009). Accordingly, researchers need to 
explore and examine the cultural influence on beliefs regarding HTN causality and severity, and 
thus medication adherence.  
In this review, higher self-efficacy was significantly related to higher medication 
adherence, as reported in four studies from Ireland, Australia, Taiwan, and Iran (Bane et al., 
2006; Chen et al., 2009; Gilbert et al., 1990; Kamran et al., 2014). Our review is consistent with 
findings from current literature among patients with other chronic illness (e.g., diabetes, arthritis, 
and cancer; Sleath et al., 2016; Van Den Bemt et al., 2014; Verbrugghe et al., 2013). Within the 
context of HTN, higher self-efficacy is also associated with higher adherence to other self-care 
behaviors related to diet, exercise, weight, and smoking (Gao et al., 2013; Walker, Smalls, 
Hernandez-Tejada, Campbell, & Egede, 2014; Warren-Findlow, Seymour, & Huber, 2012). 
Several studies showed improved medication adherence and self-care activities when self-
efficacy was incorporated as a key element in interventions such as mobile text message, health 
education, counseling, and motivational interviewing (Arora, Peters, Agy, & Menchine, 2012; 
Fisher, Hessler, Masharani, & Strycker, 2014; Moral et al., 2015; Pradier et al., 2015). This 
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indicates that self-efficacy is a critical element in behavioral changes and plays a significant role 
in medication adherence irrespective of different diseases or populations, signifying the necessity 
to empower self-efficacy across different populations to enhance adherence to antihypertensive 
medications (Easthall, Song, & Bhattacharya, 2013; Nokes et al., 2012; Pak et al., 2014). 
The majority of studies (75%) in our review reported no relationship between beliefs 
about medication necessity, effectiveness, and safety and medication adherence; this finding is 
inconsistent with Horne and colleagues’ (2013) report of a positive relationship in a majority of 
its included studies. The inconsistency in findings could be explained by: (a) variation in 
measures of beliefs about medications, as Horne’s review included studies that only used the 
Beliefs About Medicine Questionnaire (BMQ), whereas the current review did not restrict 
studies a specific measure; (b) differences in symptoms experienced by patients, as their review 
included more than 22 different chronic conditions (e.g., cancer, diabetes, HIV, asthma, and 
depression) that have more evident and severe symptoms than HTN, which could influence 
patients’ beliefs about disease and medication adherence; and (c) difference in total sample size 
included because Horne’s review included a total sample size of 25,072 compared to 6,696 in the 
current review; therefore, Horne’s review could had more power to detect a relationship between 
some beliefs and medication adherence. 
 Overall, studies included in this review showed that findings vary in addressing the 
relationship between different beliefs and medication adherence. While some studies found a 
positive or a negative relationship, others reported no relationship. This variation in findings 
could be explained by heterogeneity in (a) cultural backgrounds of populations from 14 countries 
that might hold different beliefs related to disease causality and treatment; (b) sample size, which 
ranged from 45 to 1,367 participants; (c) age, which represented a mean age ranging from 42 
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−75 years old; and (d) defining and measuring medication adherence because adherence was 
defined differently as numbers of pills taken per month using a patient report (Peltzer, 2004), as a 
total score ≥ 75% on a self-report questionnaire (Hassan et al., 2006), or as a total score of 4 
using MMAS-4 (Kamran et al., 2014). Therefore, variations in findings suggest that beliefs 
might vary across age groups, populations, and cultures indicating the need to understand 
different beliefs and how these beliefs could influence medication adherence differently. 
Therefore researchers and clinicians need to consider these variations in beliefs to design 
successful interventions sensitive to age and culture to improve adherence.  
Limitations 
These findings should take into consideration the following limitations of the studies 
reviewed. First, the majority of the studies used cross-sectional design with non-probability 
sampling, which limits causal relationships and generalizability of the findings to populations 
with HTN. Additionally, a majority of studies used self-report measures of medication 
adherence, which could introduce recall bias and overestimation of medication adherence. These 
studies also used different defining criteria for medication adherence. Therefore, future studies 
need to measure and define medication adherence objectively and consistently.  
This review is subject to several limitations inherent in systematic review. This review is at 
risk for selection and reporting bias due to the possibility of missing some relevant studies, as 
this review was limited to English full−text studies retrieved from four electronic databases. 
Therefore, non-English studies, books, dissertations, and studies obtained manually or through 
reference lists were not included. Furthermore, this review was limited to patients with HTN who 
did not have any concomitant comorbidity. Compared to those with significant findings, some 
studies with no association might not been published in the peer-reviewed journals included in 
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the databases’ searches, leading to a publication bias. Finally, studies of poor quality were 
included in reporting this review’s findings.  
Implications for Clinical Practice and Future Research 
The findings from this systematic review have several clinical and research implications. 
Clinically, healthcare providers should be aware of and assess beliefs about HTN and 
medications while caring for patients with HTN across different cultures and age groups. The 
majority of studies included in the analysis used a cross-sectional design and various measures of 
medication adherence, so future studies should focus on measuring adherence using more 
objective measures and a longitudinal design to assess long-term adherence behaviors and 
changes over time. Unlike some demographic factors (e.g., age, race, gender) that influence 
medication adherence among patients with HTN (van den Bemt et al., 2014), patients’ health 
beliefs are modifiable and could be tailored to match individual preferences or cultures. This 
necessitates early identification and incorporation of beliefs in designing effective interventions 
to foster medication adherence through reducing barriers to taking medications and maximizing 
positive beliefs about HTN and medications benefits. More studies are needed to further examine 
the relationship between beliefs about HTN severity and susceptibility to consequences and 
medication adherence because our review showed mixed findings. Furthermore, in examining 
the relationship between beliefs and adherence, future reviews could include more articles 
published in other search databases and in non-English languages, including thesis and 
dissertations.  
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Conclusion 
This review sought to systematically synthesize findings of quantitative studies 
examining the relationship between different health beliefs held by patients with HTN and 
antihypertensive medication adherence. Findings showed that fewer perceived barriers to taking 
medications (e.g., side effects) and higher self-efficacy, were related to higher medication 
adherence. Findings also showed mixed results concerning the relationships among beliefs about 
HTN severity and susceptibility to its complications and medication adherence. A majority of 
studies have not found a relationship between beliefs about medications’ effectiveness, necessity, 
and safety and medication adherence. The findings of this review emphasize the importance of 
assessing different beliefs, particularly perceived barriers and self-efficacy, integrating them in 
the clinical practice, and designing strategies to improve medication adherence. 
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CHAPTER 3: RELATIONSHIP BETWEEN MEDICATION ADHERENCE AND 
BELIEFS AMONG PATIENTS WITH HYPERTENSION IN OMAN 
Introduction 
Hypertension (HTN) prevalence is high globally and, in developing countries, HTN is 
projected to increase by 80% by 2025 (World Health Organization, 2013). Oman, a high-income 
developing country in the Middle East, also exhibits a high prevalence rate of HTN and 40% of 
Oman’s population is affected by HTN. Among those with HTN, 17% have both high systolic 
and diastolic blood pressure (BP) and 5% had severe HTN (BP ≥180/≥110) (Al Riyami et al., 
2012). Poor HTN management increases complications and related mortality and morbidity,  
(Alwan, 2011; Joffres et al., 2013) and healthcare expenditure (Gaziano, Bitton, Anand, 
Weinstein, & International Society of Hypertension, 2009). The use of antihypertensive 
medication is key to HTN management (James et al., 2014; van Vark et al., 2012), and 
expenditure reduction (Simon-Tuval, Triki, Chodick, & Greenberg, 2016); however, patient 
adherence to medications is inadequate (World Health Organization, 2013).  
Several factors contribute to poor medication adherence (AlGhurair, Hughes, Simpson, & 
Guirguis, 2012; Kardas, Lewek, & Matyjaszczyk, 2013); one of which is the patients’ beliefs 
about health and illness. Beliefs about disease severity, self-efficacy, and treatment benefits and 
concerns, as proposed by the health belief model (HBM), can drive, predict, and explain attitudes 
toward medication adherence (Janz & Becker, 1984; Rosenstock, Strecher, & Becker, 1988). 
With HTN, specifically, these beliefs have been linked to the lack of adherence to medication 
(Kamran, Ahari, Biria, Malpour, & Heydari, 2015; Pasma, van't Spijker, Hazes, Busschbach, & 
Luime, 2013).    
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Citizens of Oman, similar to those in other Arab countries, hold certain beliefs related to 
the causes of disease (e.g., evil eye or envy) and its treatment. It is probable that these same 
beliefs exist among patients with HTN, which could influence HTN management and medication 
adherence. In Oman, many studies have focused on understanding HTN risk factors and 
correlates (Al-Maqbali, Temple-Smith, Ferler, & Blackberry, 2013; Al-Mawali, 2015; El-Aty, 
Meky, Morsi, Al-Lawati, & El Sayed, 2015), but only one study examined antihypertensive 
medication adherence (El-Badawy, Al-Kharusi, & Al-Ghanemy, 2005). However, studies that 
specifically examined health beliefs and how beliefs affect antihypertensive medication 
adherence have not been identified; therefore, and because an Omani government is making an 
effort to expand its healthcare system to provide the best patient-centered care, it is important to 
understand the role of patients’ beliefs in HTN management in such a rapidly developing Arabic 
Muslim country.   
The purpose of this study was to investigate the relationship between the health beliefs of 
Omanis with HTN and medication adherence. Specifically, this study aimed to a) describe 
medication adherence and patients’ beliefs regarding HTN, antihypertensive medication, and 
self-efficacy; and b) examine the relationship between these beliefs and medication adherence in 
Omani patients with HTN. Examining health beliefs in relation to antihypertensive medication 
adherence allows clinicians and researchers to better understand the role between health beliefs 
and the willingness to take medication in managing HTN, and to effectively design screening 
protocols and strategies to foster medication adherence and BP control.  
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Method 
This descriptive cross-sectional study was conducted in Oman using four primary 
healthcare centers over a period of one month (July, 2015). Ethical approval to conduct the study 
was obtained from the University of North Carolina at Chapel Hill and the Ministry of Health 
(MOH) in Oman. 
Subjects and Recruitment 
Inclusion criteria were as follows: 1) ≥ 21 years old, 2) diagnosed with HTN for at least 1 
year, 3) prescribed at least one antihypertensive medication, and 4) spoke and understood Arabic. 
Patients were excluded from participation if they had any coexisting morbidities, which would 
require more complex treatment and could confound the relationship between beliefs and 
medication adherence (Sweileh et al., 2014).  
Patients with HTN were recruited from a total of four HTN clinics, which are weekly 
operated as a part of primary care clinics, and were screened for eligibility using a patients’ list 
obtained from medical records. Eligible patients were approached by a nurse and asked to 
participate. Study aims and procedure were explained to each enrolled subject by the principal 
investigator. Each subject signed a written informed consent, which was approved by the MOH.  
Data Collection and Measures 
In the waiting area, each subjects was asked to complete a demographic sheet and four 
Arabic version questionnaires that took 15-40 minutes to complete. These questionnaires were 
used with permission from the developers of these questionnaires1 (See Appendix 2).                                                          1 Permission to use the Arabic versions of the Morisky Medication Adherence Scale (8-items) and Beliefs 
about Medicine Questionnaire was granted from the developers, Morisky and Horne. Permission to 
translate the Brief Illness Perception Questionnaire and Medication Adherence Self-Efficacy Scale-
revised to Arabic was obtained from developers, Weinman and Ogedegbe.  
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Medication Adherence. A validated Arabic version of the Morisky medication 
adherence scale-8 items (MMAS-8) (Alhewiti, 2014; Sa’ed, Al-Jabi, Sweileh, & Morisky, 2013) 
was used to measure medication adherence. MMAS-8 is reliable and valid and consists of eight 
items; seven with a binary response (yes/no) and one with 5-responses (4 = never, 3 = once in a 
while, 2 = sometimes, 1 = usually, 0 = all the time). The items were summed, with the last item 
weighted by 1/4, giving a total sum MMAS-8 score with values between 0 and 8 (higher scores 
reflected higher adherence) (Morisky, Ang, Krousel- Wood, & Ward, 2008). In this study, 
Cronbach’s alpha of the MMAS-8 was .72 and a score of ≥ 6 represented high adherence 
(Morisky et al., 2008).  
Beliefs about Necessity of and Concerns about Medications. To measure beliefs about 
antihypertensive medication, we used a validated Arabic version of the Beliefs about Medicines 
Questionnaire-Specific (BMQ-Specific) (Jamous, Sweileh, Taha, Adham Saed El-Deen Abu, & 
Zyoud, 2014). The BMQ-Specific scale had adequate validity and reliability (Horne, Weinman, 
& Hankins, 1999) and contains two subscales that measures medication necessity (BMQ-N) and 
medication concerns (BMQ-C). The BMQ-N (five items) and BMQ-C (six items) are rated on a 
five-point Likert scale (5 = strongly agree to 1 = strongly disagree). The mean score of both 
scales ranges from 1-5; higher score reflects stronger beliefs about medication necessity or 
concerns. In our study, Cronbach’s alpha of BMQ-N and BMQ-C were .78 and .70, respectively. 
Beliefs about HTN Severity. The Brief Illness Perception Questionnaire (BIPQ) that 
was translated into Arabic for this study using international guidelines (Table 3.1) was used to 
assess beliefs about HTN severity (World Health Organization & World Health Organization, 
2009). The BIPQ, which is reliable and valid, contains eight items that assess illness 
consequences, timeline, personal and treatment control, illness identity and comprehensibility, 
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concerns related to illness, and emotions (Broadbent, Petrie, Main, & Weinman, 2006). Each 
item is rated on a 0-10 response scale with a total score of the eight items ranging from 0-80; a 
higher score represents stronger beliefs about HTN severity. Cronbach’s alpha of the BIPQ in 
this study was .68. 
Self-efficacy Regarding Medication Adherence. The Medication Adherence Self-
Efficacy Scale-Revised (MASES-R) was translated into Arabic for this study (Table 3.1) using 
international guidelines (World Health Organization & World Health Organization, 2009), and 
used to measure patients self-efficacy regarding adherence to antihypertensive medication. The 
MASES-R items (n=13) are rated on a four-point Likert scale (1 = not at all sure to 4 = 
extremely sure) with a mean score ranging from 1-4 (higher score reflects higher self-efficacy). 
The original MASES-R is valid and reliable (Fernandez, Chaplin, Schoenthaler, & Ogedegbe, 
2008). In this study, the MASES-R Cronbach’s alpha was .90.  
Table 3.1. BIPQ and MASES-R Translation Process 
1. Questionnaires were translated to Arabic by a professional bilingual native Arabic 
translator. 
2. Arabic translation was reviewed by a professional bilingual Arabic Omani translator 
residing in Oman. 
3. Arabic questionnaires were back translated to English by a professional bilingual native 
English translator. 
4. Back-translated versions were checked against original English by a professional translation 
team. 
5. Cognitive debriefing was conducted by testing the questionnaires on 10 Omani patients 
with HTN. 
BIPQ= Brief Illness Perception Questionnaire; MASES-R=Medication Adherence Self-Efficacy Scale-
Revised. 
* Translation was done according to the international guidelines 
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Data Analysis 
Descriptive statistics of means, ranges, standard deviation (SDs), frequencies and 
percentages were used to describe study variables. Prior to analysis, data normality, linearity, and 
multi-collinearity were assured using descriptive statistics, skewedness and kurtosis, visual 
inspection of histograms, P-P plots, and variance inflation factor (VIF). Relationship between 
demographics, beliefs, and adherence was assessed using bivariate analyses of Pearson 
correlation for continuous variables (i.e., age, number of years with HTN, number of 
antihypertensive medications, frequency of daily dose, BMQ-N, BMQ-C, BIPQ, and MASES-R) 
and one-way analysis of variance (ANOVA) for categorical variables (i.e., gender, governorate, 
marital and employment status, income, education level, smoking, alcohol consumption). 
Multiple linear regression analysis was used to examine the independent influence of the four 
beliefs variables (i.e., BMQ-N, BMQ-C, BIPQ, and MASES-R) on medication adherence. 
Demographic variables with a p-value < .05 in the bivariate analysis were entered in the multiple 
regression analysis. We used enter method to insert variables into the regression analysis. In this 
study, a p-value of less than .05 was considered statistically significant. In this study, we 
analyzed data from 45 subjects. This sample size provides 80% power to identify an R2 of 15.4% 
or more for bivariate regression analyses and 23% or more for multiple regression analyses based 
on four predictors. Consequently, regression analyses are only powered to identify relatively 
large effect sizes. Data were analyzed using SPSS version 23 (IBM Corp., Armonk, NY). 
Results 
Forty-five subjects with HTN, mean age 52 years (SD = 14.6), participated in the study 
(Table 3.2). The majority of the subjects were female (64.4%), residents of AL Dakhiliya 
Governorate (71.1%), married (62.2%), unemployed/housewives (57.8%), and did not smoke 
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(95.6%) or consume alcohol (97.8%). Subjects had HTN for an average of seven years and were 
prescribed two antihypertensive medications with an average of two doses per day. 
Medication Adherence 
The mean MMAS-8 score was 5.3 (SD = 2.0). Of the 45 subjects, 22 (48.9%) were high 
adherers (MMAS-8 ≥ 6). When we explored each MMAS-8 items, 95.6% of subjects reported 
that they had not missed taking medication for the last 2 weeks, 66.7% did not ever feel hassled 
about sticking to medications, 64.4% had never cut back or stopped taking medication without 
telling doctor, and 64.4% did not forget medication when they traveled. One half of the subjects 
had no difficulty remembering to take medication. 
Beliefs about Necessity of Antihypertensive Medication(s) 
 The mean BMQ-N score was 3.8 (SD = 0.79). The majority of subjects strongly agreed 
(scored 5) or agreed (scored 4) to the following:  their current  (88.9%) and future health (55.5%) 
depend on medication, medication protects their health from becoming worse (84.4%), and 
without BP medicine they would be very ill (57.8%). Of the remaining subjects, 33.3% were 
uncertain (scored 3) whether their future health depends on medications and whether their lives 
would be impossible without BP medicine.  
Concerns about Antihypertensive Medication(s) 
The mean BMQ- C score was 2.7 (SD = 0.73). More than 50% of all subjects strongly 
disagreed (scored 1) or disagreed (scored 2) to the following concern statements: BP medicine 
disrupt my life (68.2%), having to take BP medicine worries me (57.8%), and BP medicine give 
me unpleasant side effects (51.1%). At the same time, these subjects strongly agreed or agreed to 
having some concerns about becoming too dependent on medication (44.4%) and that 
medication was a mystery to them (35.5%). 
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Beliefs about HTN Severity 
The mean BIPQ score was 27 (SD = 12.2). Each item in the BIPQ is rated on a 0-10 
response scale; a higher score represents higher beliefs about HTN severity. In this study, a 
response from 0 to 5 represents lower perceptions about HTN severity. Subjects who responded 
from 0 to 5 on each BIPQ item were as follows: 70% reported that HTN has no/minimal effect 
on their lives, 100% believed in having control over HTN, 66.7% believed in having no/minimal 
symptoms from HTN, and 72.7% reported no/minimal concern regarding HTN. 
Self-Efficacy Regarding Medication Adherence 
The mean MASES-R score was 3.2 (SD = 0.67). Subjects were extremely confident 
(scored 4) in their ability to take antihypertensive medication between meals (70.5%) or more 
than once a day (59.1%), when they were worried about taking medication for the rest of their 
lives (54.5%), when they did not have any symptoms (54.5%) or felt well (52.3%), and when 
they were busy at home (50.0%).  
Relationship between Beliefs and Medication Adherence 
In the bivariate analyses, we found that stronger beliefs about HTN severity were 
correlated with lower medication adherence (r = − .32, p = .03), while higher self-efficacy was 
correlated with higher adherence (r = .44, p = .003) (Table 3.3). We did not observe a significant 
correlation between the necessity of and concerns about medication (r = .25, p = .10 and r = − 
.28, p = .06, respectively) and medication adherence or between demographics and adherence. 
Therefore, only beliefs variables and not demographics were considered in multiple regression 
analysis. When beliefs variables (BMQ-N, BMQ-C, BIPQ, and MASES-R) were entered into the 
regression model, the model was significant (F (4, 39) = 4.89, p = .003) and explained about 
33% of the variation in medication adherence. The model showed that self-efficacy (B = 1.07, p 
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= .012) and beliefs about medication necessity (B = .78, p = .028) were significantly and 
positively associated with medication adherence, and, together (i.e., self-efficacy and necessity) 
explained about 26% of the variation in medication adherence (Table 3.4). 
Table 3.2. Characteristics of Subjects 
Variable 
 
n (%) Mean (SD) Range 
Age (years)  52.1 (14.6) 23 - 84 
Years with HTN  7.3 (6.9) 1 - 30 
Number of antihypertensive medications  1.9 (1.1) 1 - 5 
Frequency of daily dose  1.6 (0.80) 1 - 4 
Scales Scores 
MMAS  
BMQ-C  
BMQ-N  
BIPQ  
MASES 
  
5.3 (2.0) 
2.7 (0.73) 
3.8 (0.79) 
27.0 (12.2) 
3.2 (0.67) 
 
0.75 – 8.0 
1.2 – 4.7 
2.0 – 5.0 
1.0 – 56.0 
1.6 – 4.0 
Governorate 
AL Dakiliya 
Muscat 
 
23 (71.1) 
13 (28.9) 
  
Gender 
Men 
Women 
 
16 (35.6) 
29 (64.4) 
  
Marital Status 
Single 
Married 
Widowed 
 
4 (8.9) 
28 (62.2) 
13 (28.9) 
  
Income (OMR) 
No Income 
<150 
150 – 499 
500 – 999 
>1000 
 
15 (33.3) 
8 (17.8) 
9 (20.0) 
2 (4.4) 
9 (20.0) 
  
Education Level 
Do not write or read 
Write and read only 
Primary or preparatory completed 
High school Completed 
University or more 
 
19 (42.2) 
4 (8.9) 
4 (8.9) 
12 (26.7) 
6 (13.3) 
  
Employment Status 
Government sector 
Private sector 
Self-employed 
Unemployed/Housewife 
Retired 
 
7 (15.6) 
4 (8.9) 
4 (8.9) 
26 (57.8) 
3 (6.7) 
  
Smoking 
No 
Yes 
 
43 (95.6) 
2 (4.4) 
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Alcohol consumption 
No 
Yes 
 
44 (97.8) 
1 (2.2) 
  
Note.  Note. HTN = Hypertension; MMAS = Morisky Medication adherence scale; BMQ-C = Beliefs 
about Medicine Questionnaire-Concern; BMQ-N = Beliefs about Medicine Questionnaire-Necessity; 
BIPQ = Brief Illness Perception Questionnaire; MASES-R = Medication Adherence Self Efficacy Scale-
Revised; OMR = Omani Rials  
 
Table 3.3. Summary of Pearson Correlations between Beliefs and Medication Adherence 
Measure Correlation (r) 
BMQ-C −.28 
BMQ-N .25 
BIPQ −.32* 
MASES-R .44** 
Note. MMAS = Morisky Medication adherence scale; BMQ-C = Beliefs about Medicine Questionnaire-
Concern; BMQ-N = Beliefs about Medicine Questionnaire-Necessity; BIPQ = Brief Illness Perception 
Questionnaire; MASES-R = Medication Adherence Self Efficacy Scale-Revised. 
* p < .05. ** p < .01. 
  
 
Table 3.4. Summary of Multiple Linear Regression Analysis for Variables Predicting 
Medication Adherence 
Variable 
 
B SE (B) Beta t p-value 95% CI 
BIPQ − 0.034 − 0.024 − 0.211 −1.389 .173 −0.83 – 0.15 
MASES-R 1.067 0.405 0.363 2.363 .012 0.25 – 1.89 
BMQ-C − 0.303 −0.402 − 0.112 − 0.755 .455 −1.12 – 0.51 
BMQ-N 0.777 0.339 0.303 2.289 .028 0.09 – 1.46 
Note. R2 = .33 
BIPQ = Brief Illness Perception Questionnaire; MASES-R = Medication Adherence Self-Efficacy Scale-Revised; 
BMQ-C = Beliefs about Medicine Questionnaire-Concern; BMQ-N = Beliefs about Medicine Questionnaire-Necessity. 
 
Discussion 
 Poor medication adherence remains a challenge and beliefs are significant factors 
influencing medication adherence. In our study, high self-efficacy was associated with 
medication adherence, which is consistent with the current literature on HTN (Fernandez et al., 
2008; Kamran et al., 2015; Schoenthaler, Butler, Chaplin, Tobin, & Ogedegbe, 2016; Warren-
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Findlow, Seymour, & Huber, 2012). The relationship between self-efficacy and medication 
adherence exists regardless of the difference in measures of adherence (e.g., MMAS-4, MEMS, 
and other self-reports) and self-efficacy (original MASES, other self-reports) or in study designs 
and population (Middle-Eastern, African American) (Fernandez et al., 2008; Kamran et al., 
2015; Schoenthaler et al., 2016; Warren-Findlow et al., 2012). Self-efficacy is key to 
completion/maintenance of health behaviors because patients need to feel empowered and to 
have confidence in performing a positive health behavior (e.g., medication adherence) (Lorig, 
Laurent, Plant, Krishnan, & Ritter, 2014). This highlights the importance of the following: 1) 
assessing self-efficacy as a central component that empowers medication adherence across 
cultures and populations and 2) designing effective and personalized strategies (e.g., action plan) 
to enhance self-efficacy to improve medication adherence and other self-care activities (Lorig et 
al., 2014).   
We found that stronger beliefs about the necessity of antihypertensive medication were 
related to higher medication adherence, which is consistent with the results of other studies, 
including those on Arabs, that examined adherence among patients with HTN and particularly 
studies that used both MMAS-8 and MMAS-4 to measure medication adherence (Kamran et al., 
2015; Rajpura & Nayak, 2014). Beliefs about medication necessity remain a key predictor of 
medication adherence for various illnesses and among populations from Europe, United States, 
Asia, and Australia, regardless of different study designs, sample sizes, or measures of 
medication adherence (Horne et al., 2013). Therefore, beliefs about medication necessity should 
be assessed and incorporated into clinical practice and, accordingly, the plan of care would be 
modified to match patients’ needs. For instance, a study to improve medication adherence by 
using text-messaging intervention has reported higher medication adherence when the text 
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message was tailored based on a previous assessment of patients’ beliefs about medication 
necessity (Petrie, Perry, Broadbent, & Weinman, 2012). Thus, health education and counseling 
could be used to facilitate the adoption of positive beliefs known to enhance adherence by 
increasing patients’ sense of power over medications used to control the disease and prevent 
complications (Pradier et al., 2015).  
We did not find a relationship between concerns about antihypertensive medication and 
medication adherence, which is inconsistent with the findings from other HTN studies (Horne, 
Clatworthy, Hankins, & ASCOT Investigators, 2010; Kamran et al., 2015; Rajpura & Nayak, 
2014). Findings from those studies revealed a negative relationship between medication concerns 
and medication adherence. In our study, the relationship was also negative, but was not 
significant. Our different findings could be the result of our small sample size, which would 
result in having less power to detect a relationship or because other studies included patients with 
coexisting morbidities that required multiple medication, resulting in patients having more 
concerns about these medications.  In our study, subjects reported having more concerns about 
becoming dependent on their medications. The low adherence level noted among patients with 
more concerns about medication could be improved by addressing these concerns in the clinical 
settings. Major concerns related to side effects, long-term effects, or dependency on 
antihypertensive medications should be clarified and discussed with patients. For instance, 
patients with HTN should be informed that, depending on the type of medication, some side 
effects could develop, but are manageable. Patients should also be aware that taking 
antihypertensive medication as prescribed is critical, safe, and well tolerated (Bramlage et al., 
2014; Khan et al., 2014).   
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Although it is not significant (which is consistent with another study), the relationship 
between HTN severity and medication adherence was negative (Sansbury, Dasgupta, Guthrie, & 
Ward, 2014). We found that as beliefs about HTN severity increased, medication adherence 
decreased, which is inconsistent with the HBM’s proposition and with the majority of studies 
that reported a positive relationship (Horne et al., 2010; Kamran et al., 2015; Rajpura & Nayak, 
2014). One reason for the negative relationship found in our study could be the influence of 
unique Islamic cultural beliefs about disease (including HTN). For instance, some Omanis might 
believe that HTN is severe and uncontrollable, but it is God’s will and fate (e.g., fatalistic 
beliefs); therefore, the patients assume a passive role, do not take medications, and rely on faith 
that the cure is in God’s hands and that prayers are the only healing option (Al Abed, Davidson, 
& Hickman, 2014; Padela, Killawi, Forman, DeMonner, & Heisler, 2012; Ypinazar & Margolis, 
2006). These beliefs are consistent with studies of Arab women, which have found that fatalistic 
beliefs present barriers for breast cancer screening (Alkhasawneh, 2007; Goldblatt, Cohen, 
Azaiza, & Manassa, 2013).  
Based on our findings and those of other literature regarding the relationship between 
illness severity beliefs and adherence, it is necessary to consider HTN-related beliefs when 
planning strategies to improve medication adherence. Clinicians should be aware that counseling 
and health education regarding HTN is effective in counteracting HTN-related negative beliefs 
that hinder medication adherence (Pradier et al., 2015). Specific attention, using a qualitative 
inquiry must be paid to investigate why Omanis who believe that HTN is a severe condition also 
demonstrate lower adherence.  
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Study Limitations  
As this study used a cross-sectional correlational design, a causal relationship and long-
term adherence cannot be inferred. Additionally, the small sample size, use of convenience 
sampling to recruit subjects from only two governorates, and inclusion of subjects with only 
HTN and no coexisting morbidities limited the generalizability of findings to a larger Omani 
population and increased the likelihood of selection bias. Therefore, researchers and clinicians 
should be cautious when using these findings in a clinical setting. Furthermore, use of a self-
report measure to examine medication adherence (MMAS-8) could introduce a recall bias and 
overestimation of adherence; therefore, additional studies should use an objective measure of 
medication adherence.  
Study Implications 
Limited evidence is available about the determinants of medication adherence among 
Omani patients with HTN. Therefore, this study contributes to the body of Omani literature 
related to HTN and medication adherence. Furthermore, our study was conducted in primary 
healthcare settings that are focal points for health prevention. Therefore, it is vital that clinicians 
and researchers be aware of how beliefs affect medication adherence, so they can assess 
medication adherence and related barriers in primary clinical settings. This is the first step 
toward improvement of HTN management and preventing HTN-related consequences.  
Future studies are needed to 1) consider the influence of unique Islamic cultural beliefs 
about illness causality and medication on medication adherence (these beliefs were not the focus 
of this study); 2) design individualized interventions (e.g., socio-behavioral, counseling, and 
educational) involving health beliefs and patient needs (Nieuwlaat et al., 2014; Pradier et al., 
2015), and 3) use a longitudinal design and a larger sample size selected randomly from different 
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sites across Oman to improve generalizability of findings and examine medication adherence 
over time. 
Conclusion 
In this study, we found that more than half of Omani patients with HTN exhibited poor 
adherence to medication and that patients’ beliefs about medication necessity and self-efficacy 
were significantly associated with medication adherence among these patients. This study 
highlighted the importance of assessing medication adherence among patients with HTN and 
demonstrated that beliefs are important factors influencing adherence beyond the demographics; 
thus, gaining more insights on improving medication adherence.
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CHAPTER 4: MEDICATION ADHERENCE AND HEALTH BELIEFS AMONG 
OMANIS WITH HYPERTENSION 
Introduction 
Hypertension (HTN) is prevalent in developed and developing countries with about 40% 
of adults having HTN globally (Alwan, 2011). In Oman, a Middle Eastern Arab developing 
country, HTN prevalence is 40.3% (Al Riyami et al., 2012) and is the leading cause of 
hospitalization (Ministry of Health, 2014). Globally, HTN is responsible for approximately 50% 
of cardiovascular and cerebrovascular events (Alwan, 2011). Though medication is key to 
managing HTN (Herttua, Tabak, Martikainen, Vahtera, & Kivimaki, 2013; James et al., 2014; 
World Health Organization, 2013), adherence to antihypertensive medication remains a 
challenge (Al Qasem, Smith, & Clifford, 2011; Chowdhury et al., 2013).   
Various factors contribute to poor medication adherence (AlGhurair, Hughes, Simpson, 
& Guirguis, 2012; Lewis, 2012), such as patients’ beliefs about illness, treatment, or the ability 
to manage health (AlGhurair et al., 2012; Khatib et al., 2014). The health beliefs model (HBM), 
which was used to guide our study, supports that a decision to take a health action (i.e., 
adherence to antihypertensive medication) is influenced by an individual’s beliefs (a) about the 
condition’s seriousness (i.e., hypertension) and his or her susceptibility to its consequences (e.g., 
stroke, cardiovascular diseases); (b) that the benefits gained from an action (e.g., blood pressure 
(BP) control) outweighs its harm (e.g., medication side effects); and c) beliefs about one’s own 
ability to perform the behavior (i.e., medication adherence self-efficacy) (Rosenstock, Strecher, 
& Becker, 1988; Strecher, DeVellis, Becker, & Rosenstock, 1986).  
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Oman is similar to other Arab/Muslim countries in that, people believe that illness 
causality is connected to God (Hodges, 2015). Therefore, Omanis with HTN may hold certain 
beliefs about HTN and its treatment that could influence medication adherence. Several Omani 
studies have examined HTN prevalence and risk factors (Al Riyami & Afifi, 2002; Al-Maqbali, 
Temple-Smith, Ferler, & Blackberry, 2013; Al-Mawali, 2015), but no published studies to date 
have examined medication adherence in relation to beliefs among Omanis with HTN.  
Hence this study was conducted to examine (a) patients beliefs about HTN, 
antihypertensive medication, and self-efficacy; (b) adherence to antihypertensive medication; (c) 
the relationship between patients’ beliefs and medication adherence; and (d) the relationship 
between medication adherence and BP control (Figure 4.1). Findings from this study will be 
helpful in identifying factors related to medication adherence among the Omani population and 
thus revealing challenges and opportunities to improve medication adherence and HTN control. 
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Figure 4.1. Study Conceptual Framework 
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Method 
Study Design, Setting, and Sample 
This descriptive cross-sectional study was conducted in Oman and targeted patients with 
HTN who received HTN care in primary healthcare centers. These primary healthcare centers 
were chosen because they were convenient for and easily accessible by the principal investigator 
(PI). Inclusion criteria were Omanis diagnosed with HTN for at least 3 months, aged 21 years or 
older, and who were taking at least one antihypertensive medication. Participants were excluded 
if they did not read or understand Arabic. Ethical approval was obtained from the University of 
North Carolina at Chapel Hill and from the Ministry of Health in Oman.   
Sample Size 
In our pilot study, the smallest correlation between medication adherence and patient’s 
beliefs was r = .25; this would have required a sample size of 117 to have 80% power to detect a 
relationship at .05 two sided significance. To be more conservative, we considered a smaller 
correlation of r = .22, which would have required a sample size of 156 to have 80% power to 
detect a relationship at 0.05 two-sided significance. We over-recruited participants to raise the 
total sample to 215 and thereby allowing for as much as 27% missing data. 
Procedure 
Recruitment. Initially, the PI obtained HTN clinics’ schedule of operation days and 
visited these clinics in every governorates on the days that the HTN clinic was operated. 
Participants visited these clinics in every governorates on the days that HTN clinic was operated. 
Participants who attended were screened for eligibility using a patient list obtained through 
electronic medical records. Eligible participants were initially approached by a nurse and asked 
to participate in the study; three participants refused to participate because they were busy and 
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could not stay longer. The PI then approached participants who had agreed to participate in the 
study and informed them about the study’s purpose and their role. Participants were asked to sign 
an informed consent form before the study commenced; they were assured that participation was 
voluntary and that refusal to participate would not affect the care they received.  
Data Collection and Measures. The principal investigator (PI) collected data from 25 
health centers of 14 wilayah (districts) in six governorates (Ad Dhakhliyah, North Ash 
Sharqiyah, Muscat, Ad Dhahirah, North and South Al Batinah). Data were collected within four 
months period (October 2015−January 2016). In the waiting room, participants completed a 
demographic sheet and self-report Arabic questionnaires on medication adherence, beliefs about 
HTN, beliefs about antihypertensive medications, and self-efficacy; these took 15−40 minutes to 
complete. The PI interviewed participants who reported reading and writing limitation in a 
private room. The PI obtained data related to BP values and comorbidity burden from the 
medical records of each patient. Permission to use all questionnaires was obtained2 (See 
Appendix 2). 
Morisky Medication Adherence Scale-8 (MMAS-8) items. We used the Arabic version 
of MMAS-8, which measures medication adherence behavior and was validated among Arabs 
(Alhewiti, 2014; Ashur, Shah, Bosseri, Morisky, & Shamsuddin, 2016; Mayet, 2016; Sweileh et 
al., 2011; Sweileh et al., 2014) with a Cronbach’s alpha ranging from .65−.80. The MMAS-8 is a 
reliable and valid scale (Morisky, Ang, Krousel- Wood, & Ward, 2008) and has been adopted in 
several languages (de Oliveira-Filho, Morisky, Neves, Costa, & de Lyra, 2014; Korb- Savoldelli 
et al., 2012; Moharamzad et al., 2014; Tandon, Chew, Eklu-Gadegbeku, Shermock, & Morisky,                                                          2 Permission to use the Arabic versions of the Morisky Medication Adherence Scale (8-items) and Beliefs 
about Medicine Questionnaire was granted from developers, Morisky and Horne. Permission to translate 
the Brief Illness Perception Questionnaire and Medication Adherence Self-Efficacy Scale-revised to 
Arabic was granted from developers, Weinman and Ogedegbe. 
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2015). MMAS-8 comprises eight items; seven items are reported as yes/no (1/0) response 
whereas the remaining item is rated on a five-point Likert scale (4 = never, 3 = once in a while, 2 
= sometimes, 1 = usually, 0 = all the time). The items are summed, with the last item weighted 
by 1/4, giving a total sum MMAS-8 score with values between 0 and 8 and with higher scores 
reflecting higher adherence. In this study, a total score of ≥ 6 indicates high medication 
adherence (Morisky et al., 2008). In the current study, Cronbach’s alpha was .64, which was 
below the acceptable value of .70. Item 7 (i.e., feeling hassled about sticking to medications) had 
the lowest corrected item-total correlation (r = .28). This item was retained because when it was 
deleted, the alpha coefficient decreased to .62.  
Beliefs about Medicines Questionnaire (BMQ). We used the Arabic version of the 
BMQ- specific that was validated among Arabs with a Cronbach’s alpha range from .70−.80 
(Alhalaiqa, Masa'Deh, Batiha, & Deane, 2015; Alhewiti, 2014; Amr, El-Mogy, & El-Masry, 
2013; Jamous, Sweileh, Taha, Adham Saed El-Deen Abu, & Zyoud, 2014; Jumah, Hassali, 
Qhatani, & Tahir, 2014) to measure participants’ beliefs about medication. The BMQ-specific 
comprised two subscales; 1) the BMQ-necessity scale (BMQ-N) that comprised five items and 
assessed beliefs about antihypertensive medication necessity, and 2) the BMQ-concern scale 
(BMQ-C) that comprised six items and assessed participants’ concerns related to medication’s 
potential adverse effects. BMQ-N and BMQ-C had adequate reliability and validity (Horne, 
Weinman, & Hankins, 1999). Both subscales were rated on a five−point Likert scale (5= strongly 
agree to 1= strongly disagree) with a mean score ranged from 1–5; a higher mean score 
represented stronger beliefs about the necessity of or concerns about medication. In our study, 
Cronbach’s alpha of BMQ-N and BMQ-C were .84 and .70, respectively.   
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Brief Illness Perception Questionnaire (BIPQ). We used the Arabic version of the 
BIPQ that was translated in the current study according to international guidelines (Figure 4.2) 
(Guillemin, Bombardier, & Beaton, 1993; Wild et al., 2005; World Health Organization & 
World Health Organization, 2009). The BIPQ comprised eight items, each assessing one 
dimension of a patient’s perception of HTN. The BIPQ had adequate reliability (Cronbach’s 
alpha = 0.72) and validity (Broadbent, Petrie, Main, & Weinman, 2006). In our study, 
Cronbach’s alpha was .52, indicating low internal consistency. Consequently, we deleted item 7, 
which had a low item-total correlation and increased the alpha coefficient to .66. Therefore we 
used the seven–item BIPQ for the analysis. Each item of the BIPQ was rated from 0–10, and the 
total summated score ranged from 0–70, where a higher score indicated strong beliefs about 
HTN severity. 
Medication Adherence Self-Efficacy Scale- Revised (MASES-R). We used the Arabic 
version of the MASES-R to assess the degree of participants’ confidence in taking their 
antihypertensive medication under certain circumstances (e.g., in public, while traveling, when 
having no symptoms). In this study, the MASES-R, comprising 13 items, was translated 
following international guidelines (Figure 4.2) (Guillemin et al., 1993; Wild et al., 2005; World 
Health Organization & World Health Organization, 2009). The MASES-R is reliable 
(Cronbach’s alpha = 0.92) and valid (Fernandez, Chaplin, Schoenthaler, & Ogedegbe, 2008) and 
was rated on four-point responses (from 1 = not at all sure to 4 = extremely sure) with a mean 
score ranged from 1–4, with a higher score indicating higher self-efficacy regarding medication 
adherence (37). In this study, the MASES-R Cronbach’s alpha was 0.93.  
Blood Pressure (BP). The PI obtained Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) readings of the day of data collection and of participants’ previous clinic visit 
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from participants’ electronic medical records. BP is considered controlled if systolic < 140 
mmHg and diastolic < 90 mmHg (James et al., 2014).  
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Charlson Comorbidity Index (CCI). We used a valid and commonly used CCI to 
collect data on comorbidities using electronic medical records (Charlson, Pompei, Ales, & 
MacKenzie, 1987; Charlson et al., 2008). The CCI score was calculated by summing the total 
weights assigned, with a higher score indicating a higher comorbidity burden. 
Demographic Questionnaire. Participants self-reported their age, gender, marital status, 
governorate, wilayah, education, monthly individual income, number of antihypertensive 
medications they take, time since they started medication, dose frequency per day, and time since 
they were diagnosed with HTN.
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Data Analysis 
 Data were analyzed using SPSS version 23 (IBM Corp., Armonk, NY). Data normality 
were assured using descriptive statistics of skewness, kurtosis, means, medians, and histograms. 
Descriptive statistics of means, standard deviations, minimum and maximum were used for 
continuous variables and of frequency and percentages for categorical variables. Bivariate 
logistic regression was used to examine the relationships of demographics, CCI, and beliefs 
(BMQ-N, BMQ-C, BIPQ, MASES-R) with having high medication adherence (MMAS-8 t 6). 
Then, multivariate logistic regression analysis using backward elimination based on the 
Step1: 
Tool translation to Arabic by professional bilingual Arabic translator 
Step 2: 
Arabic translation reviewed by professional bilingual Arabic Omani 
translator 
Step 3: 
Back translation to English by professional bilingual English translator 
Step 4: 
Back-translated version checked against original English by professional 
translation team  
Step 5: 
Pilot testing the tool on Omani patients with HTN  
Figure 2. BIPQ= Brief Illness Perception Questionnaire; MASES-R= Medication Adherence Self-Efficacy 
Scale-Revised. 
*Translation of the BIPQ and MASES-R was done by a professional international translation agent 
Figure 4.2. Translation Process of the BIPQ and MASES-R Questionnaires* 
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likelihood ratio was used to examine the independent effect of beliefs on medication adherence. 
Demographic variables that significantly related to MMAS-8 in the bivariate analysis were 
adjusted for in the multiple logistic regression analysis. Additionally, similar bivariate and 
multivariate logistic regression analyses were conducted to predict BP control and, also 
considered high medication adherence as a possible predictor. A p value < .05, a 95% confidence 
interval, and odds ratios (OR) were used to report the statistical significance and estimates.  
Results 
A total of 215 participants were included in this study (mean age = 54 years, standard 
deviation (SD) = 13.1) (Table 4.1). Participants had HTN for an average of 8 years (SD = 7.4), 
ranging from 3 months to 40 years. The majority of participants were from Ad Dakhiliyah 
governorate (30%) followed by Muscat governorate (22%). Sixty-seven percent of participants 
were female, 70% were married, 48% were not able to read/write, 96% did not smoke, 97% did 
not consume alcohol, and 36% had no income. On the day of the survey, the mean SBP and DBP 
were 140.8 mmHg (SD = 19.1) and 81.3 mmHg (SD = 11.3), respectively, and only 36% (n = 78) 
had their BP controlled. The comorbidity burden (CCI) was 1.6 (SD = 1.0), with the majority of 
participants (64%) having HTN only and the remaining participants having concurrent 
comorbidities (e.g., diabetes, myocardial infarction, heart failure, stroke). 
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Table 4.1. Characteristics of Study Participants 
 Variable 
 
n (%) Mean (SD) Range 
Age (years)  53.6 (13.1) 21 - 86 
Years with HTN  7.9 (7.4) 3m – 40y 
Number of antihypertensive medications  1.8 (0.86) 1 - 5 
Frequency of daily dose  1.5 (0.67) 1 - 4 
SBP (mm Hg)  140.8 (19.1) 102 – 200 
DBP (mm Hg)  81.3 (11.3) 49 – 110 
CCI  1.6 (0.98) 1 - 7 
Scales Scores 
BMQ-C  
BMQ-N  
BIPQ  
MASES 
MMAS-8 
  
2.4 (0.80) 
3.7 (0.86) 
25.8 (12.2) 
3.4 (0.71) 
6.4 (1.6) 
 
1 – 5 
1 – 5 
0 – 56 
1 – 4 
1.50 − 8 
Governorate 
Ad Dhakhliyah  
Muscat 
Ad Dhahirah 
Ash Sharqiyah (North) 
Al Batinah (South) 
Al Batinah (North) 
 
65 (30) 
47 (22) 
44 (20) 
28 (13) 
19 (9) 
12 (6) 
  
Gender 
Male 
Female 
 
74 (34.4) 
141 (65.6) 
  
Marital Status 
MarriedWidowed 
Single 
Divorced 
 
151 (70.2) 
44 (20.5) 
10 (4.7) 
10 (4.7) 
  
Income (OMR) 
No Income 
<150 
150 – 499 
500 – 999 
>1000 
 
77 (36.2) 
27 (12.7) 
65 (26.3) 
28 (13.1) 
25 (11.7) 
  
Education Level 
Do not write or read 
Write and read only 
Primary or preparatory completed 
High school Completed 
University or more 
 
104 (48.8) 
24 (11.3) 
31 (14.6) 
26 (12.2) 
28 (13.1) 
  
Employment Status 
Government sector 
Private sector 
Self-employed 
Unemployed/Housewife 
Retired 
 
37 (17.5) 
18 (8.5) 
4 (1.9) 
127 (60.2) 
25 (11.8) 
  
Smoking 
No 
Yes 
 
207 (98.1) 
4 (1.9) 
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Medication Adherence 
The mean score of the MMAS-8 was 6.4 (SD = 1.6). Of 215 participants, 145 (68%) had 
high adherence (MMAS-8 ≥ 6) (Figure 4.3). To explore if participants took their medications as 
prescribed, 16% sometimes forgot to take medication over the past 2 weeks and 11% did not take 
their medication on the day before the study. Reasons for non-adherence as reported by 
participants were: 1) feeling well and having their BP controlled (17%), 2) feeling hassled about 
sticking to BP medication (22%), 3) forgetting BP medication when leaving home (24%), and 4) 
having difficulty remembering to take medication (30%). 
  
Alcohol consumption 
No 
Yes 
 
209 (99.1) 
2 (0.90) 
  
Medication Adherence (MMAS-8) 
High  
Low 
 
145 (67.8) 
69 (32.2) 
  
BP control status 
Uncontrolled 
Controlled 
 
133 (63) 
78 (37) 
  
 
Note. SBP = Systolic BP; DBP= Diastolic BP; CCI = Charlson Comorbidity Index; MMAS-8 = 
Morisky Medication adherence scale-8 items; BMQ-C = Beliefs about Medicine Questionnaire-
Concern; BMQ-N = Beliefs about Medicine Questionnaire-Necessity; BIPQ = Brief Illness 
Perception Questionnaire; MASES = Medication Adherence Self Efficacy Scale; OMR = Omani 
Rials. 
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Figure 4.2 Percentage of Medication Adherence Rate* 
 
Beliefs about HTN Severity 
The mean score of the BIPQ scale was 25.8 (SD = 12.2). The overall total score of the 
BIPQ scale ranged from 0–70. Participants’ BIPQ total score ranged from 0–56 with the 75th 
percentile at 39, indicating that a large majority of the participants had a lower perception 
regarding HTN severity.  When each single item was examined, the majority of participants rated 
each item from 0–5 (perceived lower severity of HTN) for most of the BIPQ. For example, 76% 
believed that HTN does not affect or slightly affects their life, 83% believed they have some or 
total control over HTN, 77% experienced no or few symptoms from HTN, 74% had no or less 
concern about HTN, and 66% believed that HTN does not affect or has little effect on them 
emotionally. Only half of participants (55%) believed they understand HTN clearly. 
  
0%10%
20%30%
40%50%
60%70%
80%
High Adherence Low Adherence
Pe
rc
en
ta
ge
*Adherence assessed using MMAS-8
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Beliefs about Medication Necessity 
The mean score of the BMQ-N scale was 3.7 (SD = 0.9). Participants strongly agreed or 
agreed (scored 4 or 5) that their current health (70%) and future health (54%) depended on BP 
medication, that their life would be impossible without BP medication (64%), and that BP 
medication protect their health from becoming worse (85%). 
Concerns about Medications 
The mean score of the BMQ-C scale was 2.4 (SD = 0.8). When airing their concerns 
regarding medication, the majority of participants strongly disagreed or disagreed with the 
following statements: medication disrupts my life (86%), having to take BP medication worries 
me (69%), medication gives me unpleasant side effects (70%), and I sometimes worry about 
becoming too dependent on BP medication (59%). However, about 51% worried about long-term 
side effects of BP medication. 
Self-Efficacy Regarding Medication Adherence 
 The mean score of the MASES-R scale was 3.4 (SD = 0.7). The majority of participants 
were very confident in taking their BP medication when they were busy at home (70%), were 
worried about taking medication for the rest of their life (70%), did not have any symptoms 
(67%), took medication between meals (73%) or more than once a day (66%), and were traveling 
(65%). Only 58% and 48% were very confident in taking medication in public and when 
medication made them want to urinate while away from home, respectively.  
Relationship Between Medication Adherence and Beliefs 
The bivariate logistic analysis showed that those with increased age (OR = 1.07, p < .01), 
higher self-efficacy (OR = 3.39, p < .001), stronger beliefs about medication necessity (OR = 
1.82, p = .001), and those who were widowed compared to single (OR = 6.75, p = .01) were 
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more likely to have high medication adherence. On the contrary, those with stronger beliefs 
about HTN severity (OR = 0.96, p = .002) and more concerns about medications (OR = 0.30, p < 
.001) were less likely to have high medication adherence. Additionally, compared to participants 
who do not read or write, participants who had completed high school only (OR = 0.24, p = .002) 
or had university education or more (OR = 0.36, p = .02) were less likely to have high adherence.  
The variables that were significantly related to high adherence in the bivariate analysis 
were entered into multiple regression analysis. Of all variables entered (MASES-R, BIPQ, 
BMQ-N, BMQ-C, age, education and marital status), only four variables (MASES-R, BMQ-N, 
BMQ-C, age) remained after backward elimination. This reduced model was statistically 
significant (F2(4) = 84.4, p <. 001, Table 4.2) and explained 48% of the variation in medication 
adherence level (Nagelkerke R2 = .48). Three beliefs (i.e., self-efficacy, beliefs about medication 
necessity, and concern about medication) explained about 37% of the variation in medication 
adherence (Nagelkerke R2 = .37). The model revealed that 1) participants with higher self-
efficacy were two and a half times more likely to have high adherence (OR = 2.59, p < .001); 2) 
those with stronger beliefs about medication necessity were two times more likely to have high 
adherence (OR = 1.98, p = .006); and 3) those more concerned about their medication were about 
one-third as likely to have high adherence (OR = 0.34, p < .001). Additionally, the model 
revealed that high adherence is more likely with increased age (OR = 1.06, p < .001). 
Relationship Between Medication Adherence and BP Control 
The bivariate logistic analysis showed that participants with high medication adherence 
were less likely to have uncontrolled BP (OR = 0.50, p = .03) and medication adherence alone 
explained 3% of the variation in BP control (Nagelkerke R2 = .03). Additionally, the bivariate 
analysis showed that participants were more likely to have uncontrolled BP if they had the 
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following: more concern about medication (OR = 1.50, p = .03), higher comorbidity burden 
(CCI) (OR = 1.48, p = .03), and higher past SBP (OR = 1.05, p < .001) and DBP (OR = 1.48, p= 
.01). In multiple logistic regression, past SBP and medication adherence remained significant 
after backward elimination and explained 15% of the variation in BP control (Nagelkerke R2 = 
0.15) (Table 4.3). This reduced model (past SBP and adherence) was statistically significant 
(F2(2) = 23.6, p < .001). Participants with higher past SBP were more likely to have uncontrolled 
BP (OR = 1.04, p < .001), and those with high medication adherence were less likely to have 
uncontrolled BP (OR = 0.48, p = .04).   
Table 4.2. Summary of Multiple Logistic Regression Analysis for Variables Predicting 
Likelihood of High Medication Adherence* 
Variable B SE Wald df p-value Odds 
Ratio 
95% CI for 
Odds Ratio 
MASES .95 .27 12.80 1 < .001 2.59 1.54, 4.37 
BMQ-N .68 .25 7.48 1  .006 1.98 1.21, 3.23 
BMQ-C - 1.09 .268 16.48 1 < .001 0.34 0.20, 0.57 
Age 0.06 .02 15.44 1 < .001 1.06 1.03, 1.10 
Note. BMQ-C = Beliefs about Medicine Questionnaire-Concern; BMQ-N = Beliefs about 
Medicine Questionnaire-Necessity; MASES-R = Medication Adherence Self-Efficacy Scale-
Revised. 
*This model used backward elimination method and represents only the significant predictors 
of medication adherence among other variables included (Brief illness perception (BIPQ), 
education and marital status).    
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Table 4.3. Summary of Multiple Logistic Regression Analysis for Variables Predicting 
Likelihood of Uncontrolled Blood Pressure* 
Variable B SE Wald df p Odds Ratio 95% CI for 
Odds Ratio 
Past SBP# 0.04 .01 16.56 1 < .001 1.04 1.02, 1.06 
High 
Medication 
Adherence 
- .73 .35 4.47 1 .04 0.48 0.24, 0.95 
Note. SBP = Systolic BP. 
* This model used backward elimination method. Model included variables: Beliefs about medication 
concern (BMQ-C), Morisky medication adherence (MMAS-8), Charlson comorbidity index (CCI), past 
SBP and DBP.  
# SBP of the previous visit 
Discussion 
Understanding beliefs about illness, medication, and self-efficacy is critical to better 
achieving optimal medication adherence and HTN management. In this study, we found higher 
adherence is more likely in participants who have stronger beliefs about medication necessity 
and less concern about medication. These findings are in agreement with other findings among 
patients with HTN (Horne, Clatworthy, Hankins, & ASCOT Investigators, 2010; Kamran, Ahari, 
Biria, Malpour, & Heydari, 2015; Rajpura & Nayak, 2014) and among Arabs, where MMAS-8 
and BMQ were used to measure adherence and beliefs about medications (Alhalaiqa, Deane, 
Nawafleh, Clark, & Gray, 2012; Alhewiti, 2014; Sweileh et al., 2014). About 50% of 
participants reported concerns related to medications’ side effects that could develop in the 
future; therefore clinicians and scientists must assess patients’ beliefs related to medication 
concerns and necessity and then provide patients with information to help them understand the 
necessity of medication (e.g., medications’ effects and benefits against future risks) to maximize 
positive beliefs about medication and answer individual medication concerns (e.g., side effects) 
to both minimize these concerns and enhance adherence (Petrie, Perry, Broadbent, & Weinman, 
2012; Pradier et al., 2015).  
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Current studies on HTN reported mixed results regarding the relationship between beliefs 
about HTN severity and medication adherence (Chen, Tsai, & Lee, 2009; Kamran et al., 2015; 
Lulebo et al., 2015; Morrison et al., 2015). In our study, though the relationship between beliefs 
about HTN severity and medication adherence was negative, this relationship was not 
significant, which is consistent with another study that used the same measures of adherence 
(MMAS-8) and HTN severity (BIPQ) (Meinema et al., 2015). These mixed findings might relate 
to different cultural backgrounds among different populations. In Islamic culture, for example, 
regardless of the perceived severity of illness, all Muslims believe in the central role of God 
(Allah) in healing. Their behavior toward managing illness may vary; while some Muslims take 
medications, others do not because they believe that illness is God’s will and only religious 
practices and prayers will heal them (Padela, Killawi, Forman, DeMonner, & Heisler, 2012). 
This could explain the negative relationship between beliefs about HTN severity and medication 
adherence in this study.  The mixed findings also indicate that clinicians should assess these 
beliefs and be aware that such variations could exist between cultures and within Islamic culture. 
Further, in our study, half of participants reported less understanding of HTN and its 
management, so an effort to increase HTN awareness and education in Oman’s clinical and 
community settings is needed to improve medication adherence (Pradier et al., 2015).  
Our findings regarding the positive relationship between self-efficacy and 
antihypertensive medication adherence are consistent with many other studies in HTN 
(Fernandez et al., 2008; Kamran et al., 2015; Ogedegbe, Mancuso, Allegrante, & Charlson, 
2003), glaucoma (Sleath et al., 2015), HIV (Colbert, Sereika, & Erlen, 2013), and osteoporosis 
(Qi & Resnick, 2014); these studies reported the same positive association regardless of the 
different measures used for medication adherence or self-efficacy. Bandura’s self-efficacy theory 
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supported the idea that self-efficacy is a central concept that determines individuals’ behaviors 
and how much effort they spend in adopting the behavior (Bandura & Adams, 1977). This 
denotes the importance of incorporating self-efficacy into practice to increase patients’ 
confidence of their self-management behavior, particularly medication adherence. Additionally, 
using a tool such as the MASES-R in clinical areas can enable providers to identify particular 
conditions that may inhibit patients’ confidence in taking medications. Thus an individualized 
care/strategy to enhance self-efficacy should be planned. In Islamic culture, Muslims trust and 
depend on God for healing, but at the same time they believe that health is a gift, and they are 
responsible for protecting their health and seeking treatment (Hodge & Nadir, 2008; Yosef, 
2008); they then make a maximal effort to seek care and leave the outcome to God. This could 
explain why the majority of our participants demonstrated self-efficacy. We further noted that 
participants reported less confidence in taking their medication when they were in public or 
when medications made them urinate while away from home. Compared to other cultures, this 
response is not unusual because Omanis are protective and do not like to reveal their medical or 
personal issues to others, which could explain their lower confidence in taking medication under 
these circumstances.  
Consistent with previous studies, participants with high medication adherence 
significantly exhibited more BP control (de Oliveira-Filho et al., 2014; Irvin et al., 2012; 
Morisky et al., 2008; Natarajan, Putnam, Van Aarsen, Beverley Lawson, & Burge, 2013). 
Intervention studies (e.g., behavioral and educational) have shown that improving patients’ 
knowledge about HTN, its consequences, and medications’ side effects improved medication 
adherence and BP outcomes (Gwadry-Sridhar et al., 2013). Hence, for favorable outcomes 
resulting from BP control, the public health agenda should embrace assessing and improving 
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adherence to antihypertensive medication as a top priority, especially given the high prevalence 
of HTN and uncontrolled BP worldwide and in Oman.  
Findings on the relationship between age and medication adherence are currently mixed. 
Our study found that the likelihood of adherence increases significantly as age increases. Our 
findings are consistent with the majority of HTN literature (Ahmad, Ramli, Islahudin, & 
Paraidathathu, 2013; Cuffee et al., 2013; Korb- Savoldelli et al., 2012; Natarajan et al., 2013; 
Schoenthaler, Ogedegbe, & Allegrante, 2009) and with studies using MMAS-8 with a cutoff 
point of 6, specifically (Alhewiti, 2014; Lee et al., 2013). However, some studies have reported 
no relationship between age and medication adherence (Holt et al., 2013; Kamran et al., 2015; 
Sa’ed, Al-Jabi, Sweileh, & Morisky, 2013). Our findings, as supported by other literature 
findings, suggest the importance of understanding reasons for low adherence among those with 
younger ages; this is especially important as HTN prevalence is increasing among younger adults 
(Joffres et al., 2013; Nwankwo, Yoon, Burt, & Gu, 2013; Zhao et al., 2013). For example, in the 
United States, the prevalence of HTN among those 18–59 years old is 40% (Nwankwo et al., 
2013). In Oman, unawareness of HTN also is greater among those 30–39 years old as compared 
to those who are 60 and older (El-Aty, Meky, Morsi, Al-Lawati, & El Sayed, 2015), indicating 
the need to raise awareness of HTN and treatment among young Omanis.  
In this study, we found 68% of subjects had high adherence; though this percentage is not 
optimal, it is higher compared to other studies. For instance, studies among Arabs reported that 
high adherence ranges between 50% and 57% (Alhewiti, 2014; Sweileh et al., 2014); these 
studies used the MMAS-8 and defined high adherence as a score of ≥6. Other studies that used 
same or different measure of medication adherence, but different defining criteria reported an 
adherence rate that ranges from 19% to 46%  (Mayet, 2016; Rajpura & Nayak, 2014; Sa’ed et 
 90 
al., 2013). Higher adherence rate in our study compared to neighboring countries could be 
attributed to the fact that 75% of participants were 45 years or older because being older (e.g., 
>50 years) has been significantly related to higher adherence  (Alhewiti, 2014; Mayet, 2016; 
Natarajan et al., 2013). Another explanation for higher adherence among our participants 
because all Omani patients have free access to care and medications, so cost of medication would 
not be a barrier to medication adherence. 
Study Limitations 
Our findings should be interpreted in light of several limitations. First, this study is cross-
sectional, using correlation design, and cannot support a causal relationship. Second, we utilized 
the self-reporting measure of medication adherence, which may have introduced a recall bias and 
a social desirability. However, the MMAS-8 is reliable, valid, and widely used across cultures 
and populations, and has been correlated with objective measures of medication adherence (i.e., 
pharmacy refills and electronic monitoring system) (Arnet, Metaxas, Walter, Morisky, & 
Hersberger, 2015; Krousel-Wood et al., 2009). Furthermore, we used a convenience sample, 
which limited the generalizability of findings, though we used multiple primary care settings 
across Oman to obtain a heterogeneous sample. Another limitation was the low reliability of 
BIPQ and MMAS-8 (Cronbach’s alpha = .66 and .62, respectively). However, both BIPQ and 
MMAS-8 are widely used to measure perception of illness severity and medication adherence. In 
this study, we did not examine types or the actual dose of antihypertensive medications neither 
numbers and types of medications were taken to manage other concurrent comorbidities in 
relation to medication adherence, which could influence patients’ beliefs about the necessity of 
and concerns regarding antihypertensive medications and medication adherence.  
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Implications 
The findings of this study offered important implications for providers and researchers. 
Clinicians caring for patients with HTN should be aware that patients’ beliefs could influence 
their medication adherence; therefore evaluating patients’ beliefs is an important step toward 
improving medication adherence. Moreover, there is a need to design interventions aimed at 
improving medication adherence by increasing patients’ understanding of medication necessity, 
reducing perceived concerns about medications (e.g., side effects), and enhancing patients’ self-
efficacy, all of which could be achieved through patient education about HTN and medication. 
Future studies are needed to 1) modify or validate the BIPQ and MMAS-8 in the Omani 
population, and 2) examine long-term medication adherence in Oman and in the Middle Eastern 
Arab countries. Further studies could consider the effect of antihypertensive medication’s class 
and dose and of other medications taken by patients to treat concurrent comorbidities on 
medication adherence. 
Conclusion 
This study is the first to examine the relationship between beliefs and medication 
adherence in Oman using multiple cities and governorates. This study found that high medication 
adherence is more likely in people who have stronger beliefs about medication necessity, have 
fewer concerns about medications, have higher self-efficacy, and are advanced in age. Moreover, 
BP control is more likely among participants with higher adherence. The study findings set new 
priorities for future research and practice, to incorporate patients’ beliefs as a key aspect in 
optimizing medication adherence.
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CHAPTER 5: FINDINGS SYNTHESIS AND IMPLICATIONS 
First Manuscript (Chapter 2): “Beliefs and Medication Adherence in Patients with 
Hypertension: A systematic Review” 
This manuscript is a review of the state of scientific quantitative evidences examining the 
relationship between different patients’ beliefs and medication adherence for HTN. The review is 
based on the analysis of 25 quantitative studies that included patients who have HTN but do not 
have other comorbid conditions. This review represents the findings of studies from 14 countries 
around the world concerning common beliefs reported in relation to medication adherence were: 
beliefs about HTN’s severity and susceptibility; beliefs about medications’ effectiveness, 
necessity and barriers; and other patients–related beliefs (e.g., self–efficacy, patient–provider 
relationship, stress, family support, subjective norms). One major finding of this review was that 
high medication adherence was significantly related to (a) fewer perceived barriers and concerns 
related to antihypertensive medication (e.g., side-effects, high cost, and bad taste) and (b) high 
patients’ self-efficacy. This review also revealed that (a) a majority of studies found no 
relationship between beliefs about the effectiveness and necessity of medication and medication 
adherence and (b) the findings were mixed concerning the relationship between beliefs about 
HTN severity and susceptibility and medication adherence. Although some studies showed a 
positive relationship between beliefs about HTN severity and susceptibility, others reported no 
relationship.   
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Second Manuscript (Chapter 3): “Relationship Between Medication Adherence and Beliefs 
Among Patients with Hypertension in Oman” 
This manuscript, which was guided by the health beliefs model (HBM), is a report of 
findings from a pilot study aimed to examine the relationship between beliefs about HTN 
severity, beliefs about medications’ necessity, medication concerns, and self-efficacy with 
medication adherence (Figure 5.1). In this study, multiple linear regression analysis was used to 
examine this relationship. The main findings were that stronger beliefs about medications’ 
necessity and higher self-efficacy were associated with high medication adherence. Findings also 
showed no association between perceived medication concerns and beliefs about HTN severity, 
and medication adherence. Though beliefs about HTN severity were statistically negatively 
associated with medication adherence in the bivariate correlation, this relationship disappeared 
when other beliefs variables included in the model. In this study we also tested the reliability of 
the Arabic versions of the five beliefs questionnaires (MMAS-8, BMQ-N, BMQ-C, BIPQ, and 
MASES-R), by translating two questionnaires (BIPQ and MASES-R) into Arabic using 
international guidelines. Although this study was limited to 45 subjects and four healthcare 
centers, the correlation estimates findings were used to calculate the sample size required for the 
larger study, which is summarized in the following section of the third manuscript.  
Third Manuscript (Chapter 4): “Medication Adherence and Health Beliefs Among Omanis 
with Hypertension” 
This manuscript was a report of findings from the a larger study aimed to examine the 
relationship between beliefs about HTN severity, beliefs about necessity of and concerns related 
to antihypertensive medication, and self-efficacy with medication adherence. This study also 
aimed to examine the relationship between medication adherence and BP control (Figure 5.2). 
The main findings of this study indicated that patients with: (a) advanced age, (b) higher self-
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efficacy, (c) stronger beliefs about the necessity of medication, and (d) fewer concerns about 
medications were all more likely to have high medication adherence. Additionally, findings 
showed that high medication adherence is related to less likelihood of having uncontrolled BP.  
Synthesis of Findings from the Three Manuscripts 
 The main findings of the three manuscripts demonstrated that that patients with HTN 
showed high adherence to antihypertensive medication if they had (a) stronger beliefs about the 
necessity of antihypertensive medication to control BP and prevent complications, (b) higher 
self-efficacy regarding adherence to prescribed medication, and (c) fewer concerns about 
medication, both present and future medication side effects. These findings are consistent with 
the health beliefs model (Figure 5.3), which proposes that a health behavior is likely to be 
performed when an individual perceives more benefits (e.g., medications’ necessity), fewer 
barriers (e.g., medication concerns), and higher self-efficacy. In the three manuscripts, high self–
efficacy was found to be associated with high antihypertensive medication adherence, indicating 
the central role self-efficacy plays in improving medication adherence.  
Dissertation findings also indicate that adherence to antihypertensive medications is 
lower among patients with stronger beliefs about HTN severity. This finding is inconsistent with 
the health belief model, which proposes a health behavior is more likely to be performed (i.e., 
medication adherence) when an individual perceives higher severity of a condition (i.e., HTN).  
Despite its inconsistency with the health beliefs model, this finding is consistent with another 
study conducted in Egypt, which is an Arab, Muslim country (Youssef & Moubarak, 2002). The 
negative relationship could be attributed to unique Islamic cultural beliefs regarding illness 
causality and treatment, which was not within the scope of this dissertation. This might indicate 
that beliefs about HTN severity vary across different cultures and populations. 
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Implications 
Implications for Practice 
The findings of this dissertation indicate several practical implications. In primary 
healthcare settings, clinicians should consider assessments of patients’ health beliefs to be 
integral aspects of medication adherence and should incorporate them into practice. Clinicians 
need to assess and improve patients’ self–efficacy, beliefs about medications’ necessity, and 
concerns (e.g., side effects) to develop strategies personalized to patients’ needs, which will 
enhance medication adherence. Moreover, clinicians should aim to maximize patients’ positive 
beliefs about medications’ necessity and self–efficacy and reduce concerns related to 
antihypertensive medication. Patients need to be aware that antihypertensive medications are 
safe, are easily tolerated, and offset side effects when taken properly. This could be achieved by 
designing appropriate education and counseling regarding HTN and the necessity of its 
medication. Education interventions should emphasize providing patients with written or visual 
education materials (e.g., leaflet, booklets) to accommodate patients’ literacy level and fulfill 
their personal needs because our research showed that about 49% of participants do not read or 
write. 
Implications for Future Research 
The findings from this dissertation provide various recommendations for future research. 
Future studies should focus on investigating other possible beliefs that could influence 
medication adherence among patients with HTN, because in this dissertation, the focus was on 
beliefs from the health belief model. For example, in the second and third manuscripts, findings 
showed a negative relationship between beliefs about HTN severity and medication adherence, 
which was inconsistent with the findings from a majority of studies. This indicates that unique 
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Islamic cultural values or the influence of family and community beliefs might play a role in the 
relationship between medication adherence and beliefs about HTN severity. Therefore, 
qualitative studies are needed to accurately understand patients’ beliefs about HTN severity and 
how these beliefs influence medication adherence.  
Moreover, future studies using longitudinal designs and random sampling are necessary 
to optimize generalizability of findings and examine medication adherence over time and beliefs’ 
causal relationship with medication adherence. Additionally, in collaboration with clinicians, 
researchers need to design and implement interventions (e.g., educational, behavioral, and 
technological), which are personalized to individual needs to improve medication adherence. 
These interventions should focus on assessing health beliefs, maximizing positive beliefs about 
HTN and its medications, and improving patients’ self-efficacy. Finally, there is a need for future 
studies to validate the MMAS-8 and the BIPQ measures among Omanis because, in both studies, 
these measures’ reliability was below the acceptable limit. 
Implications for Policy 
Researchers, clinicians, and stakeholders need to emphasize a collaborative effort to 
improve medication adherence. Limited data is available concerning medication adherence in 
Oman; therefore, the Ministry of Health needs to incorporate medication adherence statistics into 
annual health reports, national health surveys, and the healthcare databases. Using this data, the 
government’s efforts to improve medication adherence can specifically monitored over time. 
Further, there is a need to increase awareness related to HTN and its medications. This 
awareness will improve patient’s beliefs and, thus, medication adherence. This can be achieved 
through increasing the number of community programs that are supported by the Ministry of 
Health. For instance, several successful community initiatives are available across Oman such as, 
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the Healthy Life Style program and the Healthy City Programs. These programs should be 
countrywide and focus not only on antihypertensive medication adherence, but rather adherence 
to other non-pharmacological therapeutic approaches including diet and life-style modifications 
to manage HTN and appropriately control the BP. The collaboration between stakeholders, 
scientists, and clinicians in these programs would facilitate early investigation, planning, and 
implementation of individualized and culturally appropriate strategies to improve 
antihypertensive medication adherence and management of HTN. In the Ministry of Health 
Vision 2050 (2014), it stated, “The health policy in the Sultanate of Oman considers primary 
healthcare, the most cost-effective healthcare, as the first and basic entry point for all levels of 
healthcare” (2014, p. 92), which supports the importance of examining and improving 
medication adherence in HTN and its determinants (e.g., beliefs) in primary healthcare settings. 
Conclusion 
To conclude, HTN remains a public health issue, and adherence to antihypertensive 
medication is not yet optimized. The results of this dissertation suggest that patients’ beliefs are 
significant determinants of medication adherence among patients with HTN in Oman and 
globally. Therefore, implementing strategies examining and improving patients beliefs about the 
medications’ necessity, medication-related concerns, and patients’ self-efficacy regarding 
medication adherence are essential steps for clinicians, researchers, and stakeholders to achieve 
proper patient adherence to antihypertensive medication.  
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APPENDIX 1: QUALITY ASSESSMENT TOOL OF STUDIES INCLUDED IN THE 
SYSTEMATIC REVIEW 
Appendix 2.1.  Methodological Quality Assessment Tool 
Assessment Questions Score 
1 Was the sampling method representative of the population intended to the 
study? 
 
 
A. Non-probability sampling (including: purposive, quota, convenience 
and snowball sampling)  
0 
B. Probability sampling (including: simple random, systematic, stratified g, 
cluster, two-stage and multi-stage sampling)  
1 
2 Was a response rate mentioned within the study? (Respond no if response rate 
is below 60)  
 
A. No  0 
B. Yes  1 
3 Was the measurement tool used valid and reliable?   
A. No  0 
B. Yes  1 
4 Was the measurement of adherence objective?  
A. By Questionnaire (Self-reported) 0 
B. By Clinical records or lab tests 1 
C. Both 1 
5 Did the investigator(s) control for confounding factors (e.g. stratification/ 
matching/ restriction/ adjustment) when analyzing the associations (if the study 
contains purely descriptive results, no association and prediction tests were 
conducted in the test, please select “Not applicable”)? 
 
A. No 0 
B. Yes 1 
C. Not Applicable NA 
 Scoring: Total score divided by total number of items multiplied by 100  
 Methodological Appraisal Score  
 Bad Satisfactory Good  
 0 – 33% 34 - 66% 67 – 100%  
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APPENDIX 2: PROOF OF PERMISSION TO USE THE QUESTIONNAIRES OF 
BELIEFS AND MEDICATION ADHERENCE FROM DEVELOPERS. 
MMAS-4 or 8 License Contract and Copyright Agreement  
Required citations and copyright acknowledgement for the MMAS-8 item scale are available on the 
final license contract and copyright agreement.   
In consideration for the right to use certain Morisky proprietary psychometric tools and intellectual property, the 
undersigned researcher (hereunder "Licensee" or "you") agrees to the following: 
 
A.  Ownership and Fees: All psychometric products as well as their translations, adaptations, computer programs, and 
scoring algorithms, trade secrets, and any other related documents and information (including those in electronic form) 
which embody or are related to the MMAS tools (including without limitation the Morisky Medication Adherence Scale 
4- and 8-item versions, 4-item Morisky Adherence Questionnaire, and any documentation thereof) are intellectual 
property of Donald E. Morisky, ScD, ScM, MSPH. ("Owner") Professor of Community Health Sciences, UCLA Fielding 
School of Public Health, Los Angeles, CA 90095-1772 (the address for all payments and communications related to this 
agreement).  
 
B.  Translations: Permission will only be granted to translate the MMAS tools subject to the following requirements: all 
new translations must be made by contracting with the MAPI Institute and final translations must be approved by the 
Owner.  The MAPI Institute employs the most rigorous standards in the translation process using two native linguistic 
experts to independently conduct forward and backwards translation; the Owner is actively involved in validating each 
item in the scale and grants use of the translated scale through a separate license agreement that is linked to the License 
Agreement Contract/Copyright Agreement.  Languages that have already been translated and validated by the MAPI 
Institute can be requested through the Owner/Developer, Dr. Donald E. Morisky. 
 
C. Use:  Licensee understands and agrees that 
 1) Changes to the wording or phrasing of any Morisky scale, tool or document require written permission. If any 
changes made to the wording or phrasing of any MMAS item or other Morisky document without permission, the result 
cannot be considered the MMAS, and subsequent analyses and/or comparisons to other MMAS data may violate Owner's 
rights. 
 
 2) Coding and scoring criteria of the MMAS-8 are trade secrets of the Owner and as such cannot be divulged in 
any publication or report without the Owner's prior written permission; 
 
 3) Permission to use the trademarks "Morisky," "MORISKY SCALE" or "MMAS" is not and will not be 
granted for any unauthorized use or translations of the MMAS or other MORISKY intellectual property, in whole or in 
part. No analyses, research results or publications based on unauthorized changes or translated versions, or results 
thereof, will use MORISKY, MMAS or confusingly similar attributions. 
 
 4) The MORISKY SCALE intellectual property legend on the documents provided to you must be included on 
the first page of a MORISKY SCALE questionnaire in study documents, and in any reproductions for manuscript or 
other publication purposes. The footnote must be noted at the end of the first Table or Figure that displays the MMAS-8 
items. 
 
 5) In case of scientific, administrative or intellectual property misconduct in using the MORISKY SCALE 
system of questionnaires or the Morisky name or MMAS names, Owner reserves the right to withdraw permission for use 
and to pursue all legal remedies.  Licensee agrees to the jurisdiction in and venue of the State and Federal Courts in Los 
Angeles County. 
 
 6) Rights granted under this Agreement to use the Morisky scales terminate one-year from the date below or on 
termination of Licensee's study, whichever is shorter. Licensee acknowledges understanding and agreeing to abide by the 
above requirements regarding use of any Morisky Medication Adherence Scale or other Morisky intellectual property. 
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 7) Further specific requirements, e.g., citations required in publications, may be obtained 
from the Owner via <dmorisky@ucla.edu>. Additional terms and agreements via hardcopy or email 
will become a part of and subject to the provisions of this Agreement. 
 
The license agreement is in effect for a one-year period or the duration of the study, whichever is 
shorter.  If your study is longer than one year, a renewal of license is available based upon a brief 
status report prior to expiration of the waiver of license fee and copyright agreement. 
 
If I am eligible for a waiver of license fee contractual agreement, I agree to provide Dr. Morisky a 
report of my findings upon completion of this study, cite the required references as noted on this 
waiver of license fee agreement and will comply with the copyright specification outlined above 
regarding the use of the Morisky Medication Adherence Scale, 8-Items, MMAS-8 and will abide with its 
requirements.  Please scan and email to: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of 
Community Health Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095-1772; email to dmorisky@ucla.edu. 
 
Please sign and return this contractual agreement in a PDF format, Pages 1 and 2 to Professor Morisky 
and he will provide you with pages 3 and 4 of the listing of the MMAS-8 items, scoring and re-coding 
criteria and signature authorizing full use of this copyrighted scale.  I agree to use only the English 
version of the MMAS-8 unless I purchase a validated translation of the MMAS-8 through Professor 
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